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Summary 
 
The hypothesis of the cancer stem cell (CSC) suggests that neoplastic clones are 
maintained by a rare fraction of tumor cells with stem cell properties. CSCs could 
represent disseminated dormant tumor cells without clinical signs of tumor 
progression. We used a ret transgenic mouse spontaneous melanoma model, in which 
25% of transgenic mice develop skin tumors with metastases in lymph nodes (mLN), 
liver, lungs and bone marrow (BM). Mice older than 20 weeks without macroscopic 
tumors contain in the BM tyrosinase related protein (TRP)-2-specific effector memory 
CD8
+
 T cells and show no further melanoma progression. This suggests a potential 
role of dormant tumor cells in the maintenance of memory CD8
+
 T cells. We found 
that TRP-2
+
CD133
+
 melanoma cells represent less than 1.5% of all cells in primary 
skin tumors and mLN. The majority of these cells were Ki67
—
 suggesting thereby that 
these cells could remain in a dormant state. We found an increased expression of the 
major regulator for cell survival, self-renewal, and tumor growth, HIF-1 in 
TRP-2
+
CD133
+
 melanoma cells in large tumors in comparison with those in smaller 
tumors. To investigate whether TRP-2
+
CD133
+
 melanoma cells are disseminated in 
the BM of ret transgenic mice, we performed a triple immunofluorescence staining. 
We found that only 40% of mice without macroscopic tumors contained 
TRP-2
+
CD133
+
 melanoma cells in the BM. In contrast, all tumor bearing mice 
contained TRP-2
+
CD133
+
 melanoma cells. TRP-2+CD133+  melanoma cells were 
detected in 2 of 712 (0.238%) and 4 of 1285 (0.311%) disseminated melanoma cells 
in the BM of mice without and with macroscopic tumors, respectively. We confirmed 
the dormant state of TRP-2
+
CD133
+
 melanoma cells based on the negative expression 
of Ki67 and PCNA. Proteins p16 and p27, which are typically located in the nuclei of 
dormant cells, were found in the cytoplasmic compartment of TRP-2
+
CD133
+
 
melanoma cells indicating their highly malignant phenotype. Investigating the 
interaction between memory CD8
+
 T cells with disseminated melanoma cells in the 
BM, we found that TRP-2
+
Ki67
— 
melanoma cells were co-localized with memory 
CD8
+
 T cells both in mice without and with macroscopic tumors. The proportion of 
memory CD8
+
 T cells interacting with TRP-2
+
Ki67
— 
melanoma cells was lower (less 
than 15%) in the BM of these mice. Quantitative analyses revealed that although 
certain IFN--producing CD8+ T cells interacted either with single TRP-2+ melanoma 
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cells or the smallest cluster of melanoma cells (2-5 TRP-2
+
 cells), none of these T 
cells produced perforin. Only two TRP-2-specific CD8
+
 T cells produced perforin, but 
none of them were co-localized either with TRP-2
+
 melanoma cells or TRP-2
+
CD133
+
 
melanoma cells. Furthermore, memory CD8
+
 T cells located within the large cluster 
of 50 TRP-2
+
 melanoma cells were unable to produce both perforin and IFN-. These 
findings suggest that tumor microenvironment might neutralize CD8
+
 T cell reactivity. 
In conclusion, our data demonstrate the existence of a subpopulation of CD133
+
 
melanoma cells in ret transgenic mice. Dormant TRP-2
+
 melanoma cells are able to 
interact with CD8
+
 T cells in the BM of tumor-bearing mice. 
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Zusammenfassung 
 
Nach der Hypothese der Krebsstammzellen (CSC), werden neoplastische Klone 
von einem seltenen Bruchteil der Tumorzellen mit Stammzell-Eigenschaften 
beibehalten. CSCs könnten verbreitete, ruhende Tumorzellen ohne klinische 
Anzeichen einer Tumorprogression darstellen. Wir verwendeten ein ret transgen 
Spontanmelanom- Mausmodell, in dem 25% der transgenen Mäuse Hauttumore mit 
Metastasen in den Lymphknoten (mLN), der Leber, den Lungen und im Knochenmark 
(BM) entwickeln. Mäuse, die älter als 20 Wochen sind und makroskopisch keine 
Tumore entwickeln, enthalten im BM (Knochenmark) Tyrosinase verwandtes Protein 
(TRP)-2-spezifische Effektorzellen CD8
+
 T-Zellen und zeigen keine weitere Melanom 
Progression. Dies deutet auf eine potentielle Rolle der ruhenden Tumorzellen in der 
Aufrechterhaltung von Gedächtnis-CD8
+
 T-Zellen hin. Wir fanden, dass 
TRP-2
+
CD133
+
 Melanomzellen weniger als 1,5% aller Zellen in primären Tumoren 
der Haut und mLN repräsentieren. Die Mehrheit dieser Zellen waren Ki67¯, was 
darauf hindeutet, daß diese Zellen dadurch in einem inaktiven Zustand bleiben 
könnten. Im Vergleich zu kleineren Tumoren, fanden wir in TRP-2
+
CD133
+
 
Melanomzellen großer Tumore eine erhöhte Expression von HIF-1, dem wichtigsten 
Regulator für das Überleben der Zelle, Selbsterneuerung und Tumorwachstum. Um zu 
untersuchen, ob TRP-2
+
CD133
+
 Melanomzellen im Knochenmark von ret transgenen 
Mäuse verbreitet werden, führten wir eine dreifache Immunfluoreszenzfärbung durch. 
Wir fanden heraus, dass nur 40% der Mäuse ohne makroskopische Tumore 
TRP-2
+
CD133
+
 Melanomzellen im BM (Knochenmark) enthalten. Im Gegenssatz 
dazu enthielten alle tumortragenden Mäuse TRP-2
+
CD133
+
 Melanomzellen. In 
Mäusen mit und ohne makroskopische Tumore, wurden TRP-2
+
CD133
+
 
Melanomzellen in 2 von 712 (0,238%) und 4 von 1285 (0,311%) verbreiteten 
Melanomzellen im BM von Mäusen nachgewiesen. Wir bestätigten den Ruhezustand 
der TRP-2
+
CD133
+
 Melanomzellen durch die negative Expression von (oder durch 
eine fehlende Expression) Ki67 und PCNA. Die Proteine p16 und p27, welche sich 
typischerweise in den Kernen von ruhenden Zellen befinden, wurden im 
zytoplasmatischen Kompartiment von TRP-2
+
CD133
+
 Melanomzellen gefunden, was 
auf einen hoch-malignen Phänotyp hinweist. Durch eine Untersuchung der 
Wechselwirkung zwischen Gedächtnis-CD8
+
-T-Zellen mit disseminierten 
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Melanomzellen im BM (Knochenmark) fanden wir heraus, dass TRP-2
+
 
Ki67¯-Melanomzellen sowohl in Mäusen ohne, als auch in Mäusen mit 
makroskopischen Tumoren, mit CD8
+
 T-Zellen kolokalisieren. Der Anteil von 
Gedächtnis-CD8
+
-T-Zellen, welcher mit TRP-2
+
Ki67¯ Melanomzellen interagiert, 
war  im Knochenmark (weniger als 15%) dieser Mäuse geringer. Quantitative 
Analysen zeigten, dass obwohl bestimmte IFN- produzierende CD8+ T-Zellen, 
entweder mit einzelnen TRP-2
+
 Melanomzellen oder den kleinsten 
Melanomzell-Clustern (2-5 TRP-2
+
-Zellen) interagierten, keine der T-Zellen Perforin 
produzierten. Nur zwei TRP-2-spezifische CD8
+
 T-Zellen produzierten Perforin, aber 
keine von ihnen war weder mit  TRP-2
+
 Melanomzellen oder TRP-2
+
CD133
+
 
Melanomzellen co-lokalisiert. Außerdem konnten Gedächtnis-CD8
+
-T-Zellen, die 
innerhalb des großen Clusters von 50 TRP-2
+
 Melanomzellen lokalisiert waren, weder 
Perforin, noch IFN- erzeugen. Diese Befunde legen nahe, dass das 
Tumor-Mikromilieu die CD8
+
 T-Zell-Reaktivität neutralisieren könnte. 
Zusammenfassend zeigen unsere Daten die Existenz einer Subpopulation von CD133
+
 
Melanomzellen in ret transgenen Mäusen. Ruhende TRP-2
+
 Melanomzellen sind in 
der Lage, mit CD8
+
 T-Zellen im Knochenmark von tumortragenden Mäusen zu 
interagieren. 
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IntroductionResults 
I. Introduction 
1. Tumor initiation and progression 
 
Current estimates regarding the global incidence of cancer predict that by year 
2020, the number of new cancer cases diagnosed each year will increase to 15 million 
and that the disease will be responsible for more than 12 million deaths. Despite 
recent advances in surgical techniques, radiotherapy and the development of 
molecular targeted therapies, most deaths due to cancer result from the progressive 
growth of metastases that are resistant to current therapies (1). Malignancy is a state 
that emerges from a tumor microenvironment in which the host participates in the 
induction, selection and expansion of the neoplastic cells (2). 
Malignant tumor cells recruit vasculature and stroma through production and 
secretion of stimulatory growth factors and cytokines (3-6). The hallmarks of cancer 
proposed by Douglas Hanahan and Robert A. Weinberg in 2000 and re-formulated in 
2011, elegantly summarize the multistep development of human tumors (7, 8). They 
include sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, activating invasion 
and metastasis, reprogramming of energy metabolism and evading immune 
destruction. Tumors exhibit another dimension of complexity: in addition to cancer 
cells, they contain a repertoire of recruited, ostensibly normal cells that contribute to 
the acquisition of hallmark traits by creating the ‘‘tumor microenvironment’’ (8) 
 
1.1 Primary tumors 
 
Cancer cells in primary tumors have already acquired a numbers of aggressive 
functions that will remain important throughout the rest of their metastatic progression. 
These functions generally include motility, invasiveness, resistance to hypoxia and 
reactive oxygen species, survival after detachment, and evasion of immune 
surveillance (2, 9). It has been proposed that the secondary tumor formation involves 
rare cell variants that have accumulated a complete set of genetic mutations in the 
primary tumor that enables these cells to grow in a distant organ. However, this 
hypothesis has been challenged by the detection of widespread gene expression 
patterns in primary tumors that strongly predict metastatic competence. Genetically 
marked transplantable tumors in mouse mammary carcinoma models were used to 
Introduction 
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demonstrate that cancer cells can disseminate at the premalignant stage (9). 
 
1.2 Metastasis 
 
Metastasis is responsible for approximately 90% of cancer-associated mortality, 
yet it remains the most poorly understood component of cancer pathogenesis. During 
metastatic dissemination, a cancer cell from a primary tumor executes the following 
sequence of steps: It locally invades the surrounding tissue, enters the 
microvasculature of the lymph and blood systems (intravasation), survives and 
translocates largely through the bloodstream to microvessels of distant tissues, exits 
from the bloodstream (extravasation), survives in the microenvironment of distant 
tissues, and finally adapts to the foreign microenvironment of these tissues in ways 
that facilitate cell proliferation and the formation of a macroscopic secondary tumor 
(colonization) (2, 10, 11). 
Organ-specific colonization functions have been well documented in bone 
metastasis. The ability of breast cancer cells to form typical osteolytic metastases 
requires the production of osteoclast-activating factors, such as parathyroid hormone 
related protein (PTHRP), interleukin 11 (IL-11), IL-6, Tumor Necrosis Factor alpha 
( TNF-) and granulocyte-macrophage colony-stimulating factor (GM-CSF) which 
act on osteoclasts to promote the secretion of receptor activator of nuclear-factor-kB 
ligand (RANKL), which induces osteoclast formation (12). A frequent site of distant 
metastasis, the skeletal system is composed of diverse cell types. When metastatic 
breast cancer invades bone, it frequently becomes clinically noticeable by painful 
fractures due to induced hyperactivation of bone-resorbing osteoclasts. Advanced 
prostate cancer, to the contrary, predominantly involves the stimulation of bone 
depositing osteoblasts, thus resulting in a net increase in bone density and eventual 
bone-marrow displacement (13). 
Bone metastases are a frequent complication of many cancers that lead to severe 
symptoms such as bone fractures, hypercalcaemia, and intractable skeletal pain (14) 
as well as spinal cord and nerve-compression syndromes (15). It has been estimated 
that 70% of patients with progressive breast cancer and 84% of prostate cancer 
patients develop bone metastases (14, 16, 17). Bone metastasis is often classified as 
either osteolytic or osteoblastic and one of these effects is usually predominant. For 
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example, metastases from breast and lung tumors are generally osteolytic, whereas 
metastases from prostate cancer are generally osteoblastic (15, 17-20). In a mouse 
model of melanoma metastasis (B16F10 melanoma subclone), in vivo neutralization 
of RANKL by osteoprotegerin results in complete protection from paralysis and a 
marked reduction in tumor burden in bones but not in other organs (14). 
To produce metastases via the systemic circulation, tumor cells should survive in 
the circulation, adhere to the microvascular wall of distal tissues and either grow 
locally or invade the vessel wall and grow in distant organs. Accumulating evidence 
suggests that tissue-specific gradients of chemokines play an important role in 
determining the patterns of metastasis observed in some tumors. Initial reports were 
focused on the role of CXCR4 (CD184) in breast cancer after it was determined that 
CXCL12 (stromal cell-derived factor-1, SDF-1) could be constitutively expressed by 
stroma fibroblasts in target organs of metastasis (i.e. bone, liver, lungs, and lymph 
nodes). Activation of CXCR4 on breast cancer cells has been shown to stimulate a 
number of cellular responses that are critical for metastasis formation, including actin 
polymerization, pseudopodia formation, chemotaxis, synthesis of proteolytic enzymes, 
and invasion. In addition, stimulation of CXCR4 on tumor cells promotes activation 
of integrin receptors, thereby increasing the affinity of cells for microvascular 
endothelial surface. Primary tumors that predominantly express CXCR1 
(CD181/IL-8R) preferentially spread to the brain, whereas tumors that express CCR6 
(CD196) can more likely metastasize to the pleura. Expression of CCR7 (CD197) on 
breast or melanoma cells has also been shown to be an important determinant in 
mediating skin metastasis (21). 
Several studies have shown that many tumor cells mediate their adhesion to the 
vascular endothelium by using mechanism similar to those used by leukocytes (22-24). 
E-selectin is a cytokine -inducible endothelial cell glycoprotein that is responsible for 
directing the initial localization of neutrophils to inflammatory tissues. Vascular cell 
adhesion molecule-1 (VCAM-1) is an endothelial cell glycoprotein that plays an 
integral role in promoting the firm adhesion and transmigration of blood leukocytes. 
Studies examining the adhesive interactions between melanoma and endothelial cells 
suggest that melanoma cells use their surface very late activation antigen-4 (VLA-4) 
integrin to adhere to endothelial VCAM-1(25). In a spontaneous murine model of 
melanoma, VCAM-1 was selectively up-regulated in target organs (brain, heart, and 
liver) during melanoma metastasis. (21). 
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Clinical reports have implied that the spread of carcinomas takes place primary 
through the lymphatic system and that tumor of origins are more likely to disseminate 
through the blood vascular compartment. However, this assumption is difficult to 
validate because the lymphatic and vascular systems have numerous interconnections, 
and it is well accepted that disseminating tumor cells can pass from one system to 
another. Hence, the division of metastatic pathways into lymphatic spread and 
hematogenous spread is an arbitrary one. Invasive tumor cells can easily penetrate 
small lymphatic channels and then be transported in the lymph (21). 
According to the classical model of metastasis, tumor cell dissemination occurs 
late in tumor development. Only after the primary tumor has grown, tumor cells start 
to invade the local tissue, enter the blood or lymphatic vessels, and colonize new sites 
to cause metastases (2). However, evidence increasingly indicates that single tumor 
cells spread to distant sites much earlier than previously believed (26). For example, 
single disseminated tumor cells can be found in the lymph nodes or bone marrow 
(BM) of women with a history of early-stage breast cancer that have no clinical 
evidence of metastasis or tumor recurrence. Women with such dormant cancer cells 
live with an increased risk of sudden metastases, which may occur more than a decade 
after surgical excision of the primary tumor. Similarly, single melanoma cells can be 
found in the lymph nodes of patients with thin melanomas. These single dormant 
tumor cells seem to be of prognostic relevance, due to the patients can develop 
metastases after more than 10 years of surgical excision of the tumor. Nonetheless, 
more than 90% of these patients do not develop metastases for at least 10 years after 
surgery (26). 
Early tumor cell dissemination reminiscent of the events in human metastasis has 
also been analyzed by Husemann et al. in two distinct transgenic mouse strains that 
model breast cancer (27). Although these authors did not study the latency between 
tumor cell dissemination and metastatic outgrowth, they showed that, upon adoptive 
transfer, disseminated tumor cells are capable of homing to the BM and causing 
metastases. It is noteworthy that in these breast cancer models, the tumor cells tended 
to spread to the BM and the lung, whereas in the spontaneous melanoma model used 
by Eyles et al. (28) cells spread more diffusely. Importantly, in both studies apparent 
metastatic cells bore the genetic signature of the parental tumor. Understanding why 
these disseminated tumor cells fail to cause early metastasis and what events are 
responsible for tumor dormancy are key to determining whether new therapeutic 
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interventions can be developed (26).  
 
2. Malignant skin melanoma 
 
Melanoma is often considered as one of the most aggressive and 
treatment-resistant human cancers with a median overall survival of less than one year 
(29, 30). Melanoma originates from the malignant transformation of 
pigment-producing melanocytes. As in the case of most cancer types, both genetic and 
environmental factors are believed to contribute to melanomagenesis. Melanoma 
incidence is influenced by pigmentation of the population and geographical 
parameters such as latitude and altitude, indicating that ultraviolet (UV) light has a 
causal role in melanoma development (31, 32). In fact, epidemiological studies show 
that the major etiological melanoma risk factor is UV spectrum of solar radiation, 
with the highest risk associated with intermittent burning doses, especially during 
childhood (33-35). Noonan et al. have shown that UV-A but not UV-B radiation 
requires melanin pigment to induce melanoma (36). Other genetically determined host 
factors, such as fair complexion, red hair, and multiple benign or dysplastic nevi have 
been also associated with increased melanoma risk (31). 
Melanoma progression begins with the development of either dysplastic or benign 
nevi (acquired or congenital). These can progress to the radial growth phase, in which 
the growth expands laterally but remains localized to the epidermis. At this phase, 
cells are still dependent on growth factors and are not anchorage independent or 
tumorigenic (37). Progression to the vertical growth phase is hallmarked by the 
invasion into the dermis, subcutaneous tissue and upper epidermis. In the vertical 
growth phase, cells are no longer growth factor or anchorage dependent (37). Clinical 
staging of melanoma progress from an in situ growth to one increasing in the 
thickness and vertical invasion, to regional lymph-node spread and, finally, to distal 
metastases. Vertical invasion may be representative of the degree of progression and is 
often measured by the Breslow thickness, a measure of the thickness of the tumor 
from the upper layer of the epidermis to the innermost depth of invasion (37-39). 
Melanoma is widely known to be a molecularly heterogeneous disease. However, 
it has been possible only recently to identify patients with clinical relevant molecular 
signatures and assess responses to treatment in these subgroups (40, 41). A molecular 
classification system will replace conventional histological criteria, which divides 
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melanoma into four subtypes: superficial spreading, lentigo malignant, nodular, and 
acral lentiginous (42-44). A major impetus towards etiological molecular 
classification of melanoma was the identification of an oncogenic mutation in the 
serine/threonine-protein kinase B-raf (BRAF) gene in 60% of melanoma cell lines and 
short-term cultures of primary melanoma samples (42). In 2002, it was discovered 
that cutaneous melanoma is a molecularly heterogeneous disease bearing an activating 
mutation in the gene encoding for BRAF in approximately 40% to 60% of the cases 
with 90% of the mutations resulting in a substitution of valine for glutamate at amino 
acid 600 (V600E) (30, 45). Mutated BRAF leads to constitutive activation of the 
mitogen-activated protein kinase pathway (MAPK) (30, 46). MAPK pathway is 
activated in more than 80% of melanomas (47). The dysregulation of the MAPK 
pathway can also be caused by an activating mutation in the gene encoding for the 
neuroblastoma RAS viral oncogene homolog (N-Ras) which is upstream of BRAF. In 
addition, mutations in the oncogenes C-KIT, GNAQ, and GNA11, as well as 
mutations in the tumor suppressor genes PTEN (phosphatase and tensin homolog) or 
p53, and loss of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene products 
p15 and p16, have been described (29, 37, 47). Alterations of PTEN are found in up to 
55% of melanoma metastases and combined MAPK pathway/PTEN alterations have 
been found in 20-25% of melanoma cell lines (31). 
Among the most common aberrations are those affecting the CDKN2A genetic 
locus, which ultimately controls RB1 and tumor protein p53 networks. Approximately 
10% of all melanomas are hereditary. CDKN2A is the major melanoma susceptibility 
locus in familial melanoma (48, 49). In addition to increased susceptibility to 
melanoma, inactivating germline mutations at the CDKN2A locus also increase the 
risk of other cancers, particularly pancreatic adenocarcinoma (49, 50). It is estimated 
that CDKN2A mutations contribute to 10%-40% of familiar melanoma cases. 
Frequent mutations affecting the CDKN2A locus in melanoma typically target 
p16
INK4A
, suggesting an essential role for this protein in the control of cell cycle in 
melanocytes (49, 51). The gene is deleted in approximately 50% of melanomas and is 
inactivated by point mutations in approximately 9% of the tumors (51). In addition, 
the p16
INK4A
 gene is frequently silenced by promoter methylation, a process that 
interferes with gene expression. Hypermethylation has been reported to occur in 20% 
to 75% of melanomas (49, 52, 53).  
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The MAPK signal transduction pathway, also known as the 
RAS/RAF/MEK/MAPK pathway, plays a key role in the proliferation of most solid 
tumors, including melanoma (49, 54). The signaling cascade is initiated by growth 
factor stimulation of membrane-bound receptor tyrosine kinases followed by 
activation of RAS, a small G protein with three isoforms (H-RAS, K-RAS, and 
N-RAS). Upon activation of RAS, a complex forms between RAS and one of the 
RAF serine/threonine protein kinase isoforms ARAF, BRAF, or RAF1. Once RAF is 
activated, the signal is transduced through phosphorylation of MEK leading to the 
MAPK phosphorylation, that induces a number of mitogenic and survival processes, 
including proliferation, and protection from apoptotic cell death (49). 
Often called the guardian of the genome, p53 is one of the most frequently 
mutated genes in human cancer (49, 55-58) . It is activated by many factors, including 
cellular and oncogenic stress. As a transcription factor, p53 regulates a variety of 
genes involved in cell cycle arrest, senescence, DNA repair, and cell death (59, 60). 
Under conditions of substantial cellular stress, such as DNA damage caused by UV 
radiation, the induction and activation of p53 plays an essential role in halting cellular 
growth and initiating the repair of damaged DNA. An important mediator of the p53 
cell cycle-inhibitory function is the cell cycle-inhibitor p21
WAFI/CIPI
, which inhibits the 
complex of cyclin E and cyclin-dependent kinase 2 (CDK2) (49, 61, 62). Similar to 
the inhibition of the cyclin D-CDK4/6 complex by p16
INK4A
, inhibition of cyclin 
E1-CDK2 by p21
WAFI/CIPI
 also leads to decreased phosphorylation of RB1 and, 
consequently, cell cycle arrest at the G1/S transition point (49, 61, 63). 
In contrast to most other cancers, melanomas surprisingly display a low 
frequency of p53 mutations (9%). Although most other tumors inactivate this pathway 
directly at the level of p53, melanoma appears to rely on the inactivation at the level 
of CDKN2A and its product, p14
ARF
. Most CDKN2A mutations affect p16
INK4A
, either 
alone or in combination with p14
ARF
, suggesting that it is the principal susceptibility 
gene at this locus (42, 49). 
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3. Stem cells 
3.1 Normal Stem cells 
 
  Stem cells exist in many different somatic tissues and are important for their 
maintenance and recovery. Populations of cells that derive from stem cells are 
organized in a hierarchical fashion with the stem cell residing at the apex of the 
developmental pathway (64-66). Stem cells have three distinctive properties: 
self-renewal (i.e., cell division gives rise to one or two daughter cells that retain the 
same biologic properties as the parental cell), the capability to develop into multiple 
lineages, and the potential to proliferate (67). The combination of these three 
properties makes stem cells unique. The attribute of self-renewal is especially notable, 
because its dysregulation is highly relevant to oncogenesis and malignancy. 
Aberrantly increased self-renewal in combination with the intrinsic growth potential 
of stem cells, may account for many features of malignant phenotype (68-70). 
 
3.2  Melanocyte stem cells  
 
  Visible pigmentation of the skin, hair, and eyes providing protection from 
damage by ultraviolet (UV) (71) radiation depends primarily on the functions of 
melanocytes (72) which constitute 1% of skin cells (35). The skin is the main barrier 
to external environment and relies on melanocytes to provide photoprotection and 
thermoregulation by producing melanin which can absorb UV radiation affording to 
melanocytes to be resistant to considerable genotoxic stress (36, 73). In addition to 
carotenoids and hemoglobin, melanin is the main contributor to the pigmentation in 
the skin (74). Melanin containing granules are known as melanosomes (lysosome-like 
structures) and are exported from melanocytes to adjacent keratinocytes that receive 
and distribute melanin in the upper layers of the skin (71, 75). Melanocytic stem cells 
have been identified in the murine hair follicle (76). Melanocytes in the hair follicles 
arise from melanoblasts. Melanoblasts are derived from the embryonic pluripotent 
neural crest that is a migratory population that gives rise to multiple cell lineages, 
including neurons, glial cells of the peripheral nervous system, medullary secretory 
cells, cardiac cells, craniofacial tissues, smooth muscle cells, bone, and cartilage cells 
(71, 77, 78). Melanoblast precursors can differentiate into glial precursors and 
glioblasts can potentially differentiate into melanoblasts, which explains why many 
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markers are shared between glioma and melanoma (79, 80). 
The proliferation and differentiation of melanocytes in hair follicles are closely 
coupled with hair regeneration cycle. The follicular melanocytes comprise a stem cell 
system and melanocyte stem cells reside in the upper permanent portion of the hair 
follicles throughout the hair cycle (78, 81). Melanocyte stem cells, which are 
slow-cycling cells capable of both self-renewal and differentiation into mature 
melanocytes, are specifically localized in the bulge area. The bulge in both human and 
mouse follicles is a morphological area containing quiescent cells important for hair 
follicle cycling (82, 83). To date, the best marker for mouse hair follicle bulge cells is 
CD34 (82). When melanocyte stem cells divide, at least one stem cell remains in the 
bulge while the other daughter stem cells migrate into the hair matrix and terminally 
differentiate into melanin-producing follicular melanocytes (80). 
Numerous signaling pathways and transcription factors regulate all aspects of 
melanocyte development. These include the Wnt signaling pathway (the origin of the 
name Wnt comes from a portmanteau of Int and Wg wingless from Drosophila 
melanogaster, which is the best characterized Wnt gene) (84), the G-protein-coupled 
endothelin B receptor type B (EDNRB) and its ligand, endothelin 3 (ET3; EDN3), the 
tyrosine kinase receptor KIT and its ligand KITL (also known as stem cell factor 
SCF or mast cell growth factor MGF), the hepatocyte growth factor (HGF) and its 
ligand c-MET and the transcription factors PAX3, SOX10, and 
microphthalmia-associated transcription factor (MITF) which acts as a master 
regulator of melanocyte development (78). 
Mutations in genes that are critical for melanocyte development, such as MITF, 
Pax3, the members of the Notch pathway, and Kit impair hair pigmentation. Similarly, 
mutations in enzymes involved in melanin production such as tyrosinase (Tyr), gp75 
or tyrosinase-related protein 1 (TRP-1) and TRP-2 (also called dopachrome 
tautomerase) result in either albino mice (tyrosine mutations) or brown mice (TRP-1 
and TRP-2 mutations) (71, 80). There are two main types of melanin, red/yellow 
pheomelanin and brown/black eumelanin (71). Both melanins derive from a common 
tyrosine-dependent pathway with the same precursor, tyrosine. TRP-1 and TRP-2 
share 40%-45% identity with tyrosinase and are useful markers of differentiation (80, 
85).  
 
Introduction 
20 
Tyrosinase, TRP-1 and TRP-2 were shown to represent enzymatic components of 
melanosomes (75, 86, 87). The main structural component of melanosomes is 
melanocyte-associated protein 17 (Pmel-17, also known as gp100 or SILV), whose 
sorting involves adaptor protein 1A (AP1A), AP1B, AP2 and spectrin, as well as a 
chaperone-like component, melanoma-associated antigen recognized by T cells 1 
(MART-1) (88). During their maturation, melanosomes move from the perinuclear 
area towards the plasma membrane. Microtubules, dynein, kinesin, actin filaments, 
Rab27a, melanophilin, myosin Va and Slp2-a are involved in melanosome transport 
(75). 
 
4. Cancer stem cells (CSCs) 
 
  The CSC model has suggested that only small subpopulations of cancer cells 
have tumorigenic potential. CSCs exhibit properties of normal stem cells such as the 
ability of self-renewal by symmetric division, the capacity to form cell clones with a 
higher rate of differentiation and proliferation by asymmetric division (89-97). In 
general the CSC concept suggests that many tumors are hierarchically organized with 
these putative CSCs being at the top of the hierarchy (89-96). CSCs are genetically 
identical to the rest of the malignant clone, but constitute the only cell type with tumor 
propagation potential within the overall tumor population (98). Simultaneously, they 
show significant resistance to radiation and chemotherapy due to their distinctive 
properties which seem to be related to their stem-like character (99). Thus, although 
these therapies often significantly reduce the bulk of tumor cells, resistant CSCs can 
be retained in the body, leading to the frequently observed relapse and metastasis 
formation after initially successful cancer therapies (95, 99). 
Although populations of tumor cells containing CSC activity have been identified 
in various solid cancers including brain, breast, colon and prostate tumors, the search 
for reliable markers to identify CSCs is still ongoing (100, 101). It appears that 
marker expression on CSCs depends on tumor type and stage as well as on mutations 
present in each individual tumor. Moreover, the expression of certain markers on 
CSCs may not be stable within the tumor at any stage and time making it notoriously 
difficult to identify reliable general markers for CSCs in vitro or in vivo (91, 98). In 
addition, not all types of cancers are hierarchically organized and even in those that 
are, the hierarchy may flatten during tumor progression towards highly metastatic 
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“undifferentiated” cancers, in which tumor cells show CSCs properties (89, 98, 102, 
103). Diverse CSC markers haven been reported including CD20 (104, 105), CD24 
(106-109), CD34 (110), CD44 (111-114), CD166 (115), nestin (116-118), 
multidrug-resistance transporter ABCB5 (119-123) and CD271 (124, 125). 
Alternatively, JARID1B, and aldehyde dehydrogenase (ALDH) have been described 
as melanoma stem cell markers. JARID1B is a molecular marker for slowly cycling 
cells and has been associated with stem cell maintenance. In human embryonic stem 
cells, JARID1B blocks terminal differentiation and mediates cell cycle arrest. In 
melanoma, only approximately 1% of cells exhibit high expression of JARID1B (126). 
Aldehyde dehydrogenase (ALDH) enzyme activity has been identified as a stem cell 
marker in normal human hematopoietic stem cells and in multiple tumors. 
Boonyaratanakornkit et al. demonstrated that ALDH
+
 melanoma cells displayed 
robust self-renewal, whereas ALDH¯ cells showed minimal self-renewal in vitro. 
Thus, ALDH
+
 melanoma cells have enhanced tumorigenicity and superior 
self-renewal ability compared to ALDH¯ cells (127). On the contrary, Prasmiclaite et 
al. argued that ALDH phenotype is not associated with more-aggressive 
subpopulations in malignant melanoma (128). Santini et al. have shown that ALDH
+
 
melanoma cells express high levels of embryonic pluripotent stem cell factors Sox2, 
Nanog, Oct4 and Klf4 (129). CD133 has been described as the most relevant CSC 
marker, since it has been linked to tumor-initiating cells and implicated in tumor 
progression (130-133). 
A number of mechanisms have been suggested to explain the exquisite resistance 
of CSCs to radio- and chemotherapies. For example, CSCs and normal stem cells 
express various ABC transporter pumps that export small molecules (drugs) out of the 
cell (99). They also have very efficient DNA repair mechanisms and are thought to be 
located in hypoxic extracellular matrix rich niches, which would mediate resistance to 
the radiotherapy-induced DNA damage and prevent drugs from reaching sufficient 
high concentrations within CSCs (134, 135). Finally, like many normal stem cells 
CSCs may also divide only rarely or at least are transiently in a state of deep 
long-term quiescence called dormancy. Such a state would make them resistant to 
anti-proliferative and other chemotherapeutic regimens as they are not only 
non-cycling, but also require little energy or oxygen making them insensitive to 
signaling pathway inhibitors (89). 
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4.1 Regulation of cancer stem activity 
 
  CXCR3 (CD183) and CXCR4 (CD184) have been described as master regulators 
of metastasis (136, 137), whereas vascular endothelial growth factor receptor 1 
(VEGFR1) (138), and VEGFR2 (139) are essential factors to promote angiogenesis 
(140, 141). Approximately 60% of metastasis in malignant melanoma is found in 
regional lymph nodes (142). It has been demonstrated that CXCR3 plays a critical 
role in lymph nodes metastasis of melanoma (B16F10 cell line) (142), colon (143) 
and breast cancer (144). Expression of CXCR3 was found in 31 cases (33.7%) out of 
92 human colon cancer specimens from cases most of which had lymph nodes 
metastasis (145). Importantly, the patients with CXCR3
+
 colon cancer showed 
significantly shorter survivals than those without CXCR3. In addition, the patients 
with tumor double positive for CXCR3 and CXCR4 had significantly poorer 
prognosis than those with tumors positive only for CXCR4 or the double negative 
(144). Scala et al. reported that CXCR4 expression was detected in 33 out of 63 
(52.4%) metastases from cutaneous melanoma (146). The metastatic potential of 
primary melanoma is considerably higher than other primary solid tumors when 
comparing the size of primary lesion (146). 
Hypoxia, a condition of insufficient oxygen availability, occurs during normal 
development as well as tumorigenesis. Cellular responses to hypoxia are primarily 
mediated by hypoxia-inducible factors (HIFs) such as HIF-1α (147). Cancer stem 
cells are critically dependent on HIF-1α for survival, self-renewal, and tumor growth 
(148). HIF activity in a rare subset of hypoxic tumor cells such as CSCs, may enhance 
the expression or activity of specific signaling pathways such as Notch and the 
expression of transcription factors such as Oct4, Sox2, Klf4, c-Myc, ABCB 
transporters, and telomerase to promote further dedifferentiation and confer stem 
cell-like properties (148, 149). Hypoxia may increase metastatic homing by inducing 
CXCR4 expression in renal cell carcinoma (150), ovarian cancer (151), breast cancer 
(152) and lung cancer (153, 154). McCord et al. showed that hypoxia not only 
increased the fraction of CD133-positive cells, but also enhanced the stem-like 
phenotype of several cell lines (155). Soeda et al. demonstrated that hypoxia promotes 
expansion of the CD133-positive glioma stem cells through activation of HIF-1α 
(156). Propagation of the glioma-derived CSCs in hypoxia environment also led to the 
expression of cells bearing CXCR4 (156). Kim et al. found that CXCR4
+
CD133
+
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B16/F10 melanoma cells exhibit higher metastatic activity compared to 
CXCR4
¯
CD133
+ 
cells, and blockage of CXCR4 coupled with dacarbazine efficiently 
inhibited both tumor growth and metastasis (157). Kumar et al. described that 
BRAF
V600E
 mutation increases HIF-1α expression and melanoma cell survival under 
hypoxic conditions (158). It was shown that HIF-1α enhances CD39/CD73 function 
on epithelial cells to protect the epithelial barrier during hypoxia (159); it is well 
accepted today that CD39 and CD73 are potent suppressor of antitumor responses. 
Cancer exosomes were described to express CD39 and CD73, which suppress T cell 
through adenosine production (160). Thus, hypoxic microenvironments contribute to 
cancer progression by activating adaptive transcriptional programs that increase tumor 
glycolysis, promote cell survival, motility and tumor angiogenesis (148, 154). 
 
4.2 Melanoma stem cells 
 
  A subset of melanoma cells endowed with the capacity to induce tumor growth 
and metastasis has been recently identified (161, 162). These melanoma-initiating 
cells express ABCB5, conferring resistance to chemotherapy, as well as stem cell 
markers CD133, CD271 and nestin, which seem to be of functional relevance for 
melanoma-initiating cells, since the blocking ABCB5, CD271 or CD133 reduced the 
capacity of melanoma cells to metastasize (161, 162). Moreover, it has been 
demonstrated that the frequency of melanoma-initiating cells could be dramatically 
higher (102, 163, 164). 
 
4.3 CD133 as melanoma stem cell marker 
 
CD133 (Prominin-1) was the first identified member of the Prominin family of 
pentaspan membrane proteins. The specific functions and ligands of the Prominins are 
still relatively unclear, but they are distinct in their restricted expression within plasma 
membrane protrusions, such as epithelial microvilli and epididymal ductal epithelial 
sterocilia, and hence their name derives from the Latin prominere, meaning “to be 
prominent” (165). In 1997 a novel monoclonal antibody (mAb) that recognized the 
AC133 antigen (human CD133), was produced, whose restricted expression in CD34
+
 
progenitor populations from adult blood, BM and fetal liver cells implied its function 
as a marker of hematopoietic progenitor cells (166). AC133
+
 cells are believed to be 
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more primitive than CD34
+
 cells. In the same year, Weigmann et al. generated a 
murine mAb termed 13A4 and described its corresponding antigen, Prominin (167). 
Prominin was enriched in the apical microvilli of mouse embryonic and adult 
neuroepithelium and the microvillar tips of the kidney brush border cells. Human and 
mouse CD133 show only 60% identity (165). 
CD133 has been expressed in a number of CSCs identified to date in brain (168, 
169), pancreas (170), prostate (171-173), lung (174), liver (175, 176), and colon 
tumors (177, 178). In brain, CD133 is highly expressed in CSCs from 
medulloblastoma (179) and glioblastomas (180, 181) and has been used to isolate 
these CSCs and characterize their highly tumorigenic potential. However, it is not 
clear how CD133 contributes to CSC characteristics such as resistance to the therapy 
(181, 182), the ability to self-renew and the potential to differentiate (183, 184). 
CD133-positive cervical tumor cells were described to be enriched in vaccinated mice 
(185). The poor clinical outcomes of vaccination are caused by the immune-resistant 
and stem-like phenotype within the tumor microenvironment promoted by the 
transcription factor Nanog which plays an important role for self-renewal of 
embryonic stem cells (185). 
 
5. Dormant tumor cells 
 
  Cancer dormancy, mentioned first in 1864, re-emerged in 1934 (186) and was 
confirmed in 1959 (187). It has been historically defined in clinical terms, namely 
recurrence of the cancer systemically or locally a long time after removal of the 
primary tumor in a patient who has been clinically disease-free (188). Tumor 
dormancy is a phenomenon characterized by tumor cells persisting in the host for a 
long time (for months or years) as non-proliferative (189) solitary tumor cells or as 
micrometastases whose cellular proliferation is counterbalanced by apoptosis (i.e., 
tumor mass dormancy and/or angiogenic dormancy) (190). In several experimental 
models, the immune system controls dormancy (191). Consequently, tumor dormancy 
is a stage in cancer progression, in which residual disease is present but is not 
clinically apparent (190). The most exciting aspect of clinical cancer dormancy is 
resembles a chronic disease, a state of disease persistence without symptoms or signs 
unless this balance is disturbed and a relapse occurs (188). 
In the experimental settings, such as in xenograft models a “dormant” tumor can 
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be defined by its microscopic size and stable non-expanding mass. In more details, 
dormant tumors are characterized by: 
a) Tumor growth in vivo to 1 mm in diameter or less, at which time further 
expansion ceases; 
b) Inability to induce angiogenic activity due to lack of intra-tumoral microvessels, 
or active repulsion of extending blood vessels in the local microenvironment. 
These tumors are white or transparent on gross examination; 
c) Expression of equal or higher amounts of anti-angiogenic (i.e. thrombospondin-1) 
factors compared to angiogenic (i.e. vascular endothelial growth factor, VEGF 
and basic fibroblast growth factor, bFGF) proteins;  
d) Active tumor cell proliferation, apoptosis in vivo, and metabolic activity during 
the dormancy period; 
e) Inability to spontaneously metastasize from the microscopic dormant state; 
f) Harmlessness to the host until they switch to the angiogenic phenotype (192-194). 
Metastatic dormancy of melanoma has not yet received sufficient attention, most 
likely because once detectable metastasis is almost invariably fatal and, the focus has 
been on finding ways to prolong life of patients with overt recurrences. Some 
melanomas have an ability to disseminate early during primary tumor progression and 
once disseminated to remain undetected (dormant) for years. Tumor dormancy 
mechanisms can be largely grouped in two categories: dormancy of a tumor mass and 
dormancy of solitary tumor cells (195). 
Angiogenic metastatic dormancy applies to the dormancy of tumor mass. In this 
case a micro-metastatic lesion actively proliferates but it does not expand because it is 
avascular. The inability to recruit blood vessels is likely caused by the lack of 
expression of angiogenesis factors such as VEGF, and/or high expression of 
angiogenesis inhibitors such as thrombospondin (195, 196). It has been shown that 
human melanoma micrometastases are poorly vascularized and have lower rates of 
tumor proliferation as compared to melanoma macrometastases (195, 197-200). 
Disseminated predominantly solitary tumor cells isolated from BM of patients 
bearing cancers of different origins are negative for markers of proliferation such as 
proliferating cell nuclear antigen (PCNA) or Ki67, suggesting that they can enter a 
state of cellular quiescence or dormancy. It was shown that solitary melanoma cells 
(B16F10 tumor cells) which metastasized to the lungs were dormant and did not 
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express markers of apoptosis (201). The experience from preclinical models suggests 
that tumor cells can enter dormancy if certain signaling pathways are malfunctioning 
and/or activated. The most common mechanism is a G0/G1 arrest with high expression 
of p21 and p27 (195, 198-200). The BM also serves as reservoir for dormant tumor 
cells that are resistant to chemotherapeutic treatment (15). Hence, BM might be an 
important reservoir that allows for disseminated tumor cells to adapt and stay hidden 
without clinical signs of observable metastases (202). Thus, dormant tumor cells 
arrested in the BM may act as a possible source of tumor cells that can be 
systemically released in different periods, leading to the relapse in patients that 
seemed to be clinically cured (203, 204). Furthermore, it has been documented that 
leukemic cells create BM niches that causes hematopoietic stem cell (HSC) 
dysfunction by usurping normal HSCs (202). Tumor derived exosomes may induce 
the suitable pre-metastatic niche for the attraction of tumor cells to the BM (205). 
 
5.1 Dormant tumor cells and immunosurveillance 
 
The original concept of tumor immunosurveillance postulated that most 
malignant tumors that arise are eliminated via lymphocyte-mediated responses before 
they become clinically detectable (26, 206). Therefore the adaptive immunity could 
constantly inhibit the emergence of neoplastic clones and thereby act as a major 
protector from the development of cancer (188, 207). However, some investigators 
argued that tumor cells did not possess the appropriate “danger signals” needed to 
alert the immune system, whereas others suggested that the immune system would 
ignore or tolerate a developing tumor because tumor cells were too similar to the 
normal cells from which they were derived (207). 
The immune system plays at least three distinct roles in preventing cancer: (i) it 
protects the host against viral infection and hence suppresses virus-induced tumors; (ii) 
it prevents the establishment of an inflammatory environment that facilities 
tumorigenesis by eliminating pathogens and by prompt resolution of inflammation; 
and (iii) it eliminates tumor cells in certain tissues because nascent transformed cells 
often co-express ligands for activating receptors on innate immune cells and tumor 
antigens (207).  
The discovery that the immune system not only controls tumor quantity but also 
tumor quality (immunogenicity) prompted a major revision of the cancer 
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immunosurveillance hypothesis. This study revealed that tumors formed in mice that 
lacked an intact immune system were more immunogenic than similar tumors derived 
from immunocompetent mice. The notion that the immune system not only protects 
the host against tumor formation but also shapes tumor immunogenicity is the basis of 
the cancer immunoediting hypothesis (207). Cancer immunoediting process, in its 
most complex form, proceeds sequentially through three distinct phases termed 
“elimination”, “equilibrium”, and “escape” (207). 
In the elimination phase, innate and adaptive immunity work together to destroy 
developing tumors long before they become clinically apparent. If, a rare cancer cell 
variant is not destroyed in the elimination phase, it may then enter the equilibrium 
phase, in which its outgrowth is prevented by immunologic mechanisms. T cells, 
IL-12 and IFN- are required to maintain tumor cells in a state of functional dormancy, 
whereas NK cells and other cells of innate immunity are not required (208, 209). 
Editing of tumor immunogenicity occurs in the equilibrium phase. Equilibrium may 
also represent an end stage of the cancer immunoediting process and may restrain 
outgrowth of occult cancers for the lifetime of the host. However, as a consequence of 
constant immune selection pressure placed on genetically (210) unstable tumor cells 
held in equilibrium, tumor cell variants may emerge that (i) are no longer recognized 
by adaptive immunity, (ii) become insensitive to immune effector mechanisms, or (iii) 
induce an immunosuppressive state within the tumor microenvironment (207-212). 
These tumor cells may then enter the escape phase, which correspond to clinically 
apparent disease (207-212). Nanog, which is induced as a consequence of immune 
selection, enhanced the stem-like features of tumor cells and protected them from 
killing by tumor-reactive cytotoxic T cells (CTLs) (185).   
It has been described that dormant tumor cells were more resistant to apoptosis 
induced by specific CTLs because they express more B7-H1 (PD-L1 / CD274), and 
such expression was proportional to the time they had persisted in the host (191). 
These data indicate that tumor dormancy may result from a balance between host 
immune response and active mechanisms developed by tumor cells to escape from 
CTLs (191). 
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6. Melanoma-specific T cells 
 
  T cells have an essential role in protection against a variety of bacterial and 
viral infections (213, 214). The fundamental characteristic in describing a T-cell 
response is its magnitude. This is commonly represented by the frequency of 
antigen-specific T cells or the expression of a specific effector function, such as IFN- 
production (213). CD8
+
 T cells are a part of the adaptive branch of the immune 
system and key players in mediating immunity to intracellular pathogens and tumors. 
Recognition of self-antigens on cancer presents problems. First, immunity to 
cancer may not develop because of immune tolerance. Second, even when the 
immune system can recognize and respond to self-antigens, immunity may not be 
sufficient to reject cancers. Finally, if immunity to self-antigens develops, there are 
potential autoimmune sequelae (215). Therefore, it is important to keep in mind, that 
the antitumor immunity may be limited and often insufficient to destroy a rapidly 
growing neoplasma, including its CSC pool, which arises from the organism´s own 
tissue and therefore predominantly expresses self-antigens (as TRP-2) to which host 
immune cells have been tolerated (216). Identification of tumor associated antigens 
(TAA) that can be recognized by CTLs has been a major advancement in 
understanding tumor immunity. Because TAAs are self-antigens, immune responses 
against them are regulated by central and peripheral tolerance mechanisms (217). 
Generally, highly self-reactive CD8
+
 T cells are deleted during thymic development. 
However, deletion of self-reactive CD8
+
 T cells is incomplete and self-reactive CD8
+
 
T cells can escape thymic selection and persist in the periphery under the control of 
several regulatory mechanisms, including anergy, ignorance, suppression, and deletion  
(217).  
The majority of the human tumor-antigens characterized to date are derived from 
non-mutated self-proteins (85). TRP-2 is a non-mutated, self-protein (melanoma 
associated self-antigen) with a low immunogenicity that is expressed by both 
melanocytes and melanomas. It is an epitope recognized by both human and murine 
CTLs and is presented by the major histocompatibility class I haplotypes HLA-A0201 
and H-2K
b
, respectively (85, 217, 218). Vaccination with recombinant TRP-2 
protein-pulsed dendritic cells (DCs) induced TRP-2-specific CTLs and immunity 
against B16 tumor (218, 219). In addition, vaccination with TRP-2 peptide-loaded 
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DCs delayed B16 tumor growth and prolonged mouse survival (219, 220). Analysis of 
the response in treated mice revealed elevated levels of CD8
+
 T cells specific for a 
peptide consisting of residues 180-188 of TRP-2 (TRP-2180-188). There was no 
evidence of reactivity to the melanocyte antigens gp100, tyrosinase, 
MART-1/Melan-A or TRP-1 (219, 221). The development of effective antitumor 
responses is normally constrained by low-avidity, tumor-specific CTLs that are unable 
to eradicate the tumor. 
In recent years, T cell receptor transgenic (TCR-Tg) mouse models have provided 
crucial new insights into mechanisms driving vitiligo and effective melanoma 
immunotherapy. The pmel-1 CD8 TCR-Tg mouse was the first of such models, 
possessing a TCR specific for gp10025-33 in the context of D
b 
(222, 223). In addition to 
Pmel mice, a TRP-2 specific TCR-Tg mouse with specificity for TRP-2180-188 (termed 
clone 37) was more recently generated. These mice do not develop spontaneous 
vitiligo, and adoptive transfer of naïve Tg T cells fails to induce rejection of 
established B16 tumors. The low potency of these cells may be a reflection of a lower 
avidity TCR, as clone 37 was originally raised by vaccination of wild-type mice with 
murine TRP-2 (217, 222). A third model with specificity for Tyr369-277 in the context of 
HLA-A2.1 expresses the TCR from a CD8 T cell clone that was isolated following 
vaccination of albino (tyrosinase-deficient) HLA-A2.1 transgenic mice (224, 225). In 
contrast to Pmel, clone 37 mice and Tyr369-277 TCR Tg mice develop robust vitiligo 
(222). A fourth model generated in 2008 represents an MHC class II-restricted, TCR 
transgenic mouse model in which CD4
+
 T cells recognize a novel epitope in TRP-1. 
Th1 cells are the most important in tumor rejection, whereas Th17-polarized cells 
more effectively mediated destruction of advanced B16 melanoma. Their therapeutic 
effect was critically dependent on IFN- production (226). 
 
6.1 Memory T cells 
 
Memory cells have several functional properties that distinguish them from naive 
cells, such as (a) an ability to respond to lower antigen concentrations, (b) faster 
proliferation following antigenic stimulation, (c) more rapid display of effector 
functions, (d) the potential to release a broader spectrum of cytokine, and (e) a pattern 
of adhesion molecules that allows access to peripheral tissues (227, 228). Moreover, 
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memory T cells are less dependent on costimulation provided by antigen-presenting 
cells (APCs) and can divide in the periphery long after antigen stimulation, sometimes 
even without any evidence for the persistence of their cognate antigen (227). BM of 
breast cancer patients was found to contain CD8
+
 T cells specific for peptides derived 
from breast cancer-associated proteins (227). These tumor-infiltrating cells had a 
central or effector memory phenotype and produced perforin (227). Moreover, it has 
been shown a selective homing of memory T cells to human tumors which suggests 
that tumor rejection is based on the recognition of TAA on tumor cells and dendritic 
cells by autologous specifically activated central and effector memory T cells (227). 
It has been reported that tumor cell-vaccinated mice harbor in their BM small 
numbers of dormant tumor cells and also memory T cells that provide protection 
against further tumor cell challenge (229, 230). The BM of breast cancer patients was 
enriched for tumor-specific memory T lymphocytes (231). Such T cells could be 
stimulated in vitro to produce IFN-γ and to acquire antitumor cytotoxicity in vitro and 
in vivo (227). Thus, BM could be considered as a major site for long-term persistence 
of tumor-specific memory T cells and of small numbers of dormant tumor cells that 
are kept under active host immune T cell control (228). Using a ret transgenic mouse 
melanoma model, it has been shown BM of mice without macroscopic primary 
tumors contain high frequencies of CD8
+
 T cells specific for TRP-2 and showing 
mostly effector memory phenotype (232). Moreover, increased numbers of BM 
TRP-2-specific effector memory CD8
+
 T cells were also detected in transgenic 
animals older than 20 weeks with disseminated melanoma cells in the BM and lymph 
nodes but showing no visible skin tumors and no further melanoma progression (232). 
These data indicate that functionally active BM-derived melanoma-specific memory T 
cells are detectable at the phase of microscopic tumor load, suggesting that thereby 
they could control disseminated melanoma cells (232). 
Memory CD4
+
 and CD8
+
 T cells can be divided into two subsets, TCM (Central 
memory T lymphocytes) and TEM (Effector memory T lymphocytes) are defined based 
on two distinct criteria: (a) the presence of immediate effector functions and (b) the 
expression of homing receptors that allow cells to migrate to secondary lymphoid 
organs versus non-lymphoid tissues. In mouse, central memory CD4
+ 
T cells (CD4
+
 
TCM) show CD45RB
¯
 CD62L
+
 whereas effector memory CD4
+
 T cells (CD4
+
 TEM) 
show CD45RB
¯
 CD62L
¯
 phenotype. On the other hand, central memory CD8
+
 T cells 
(CD8
+
 TCM) display CD44
high
 CD62L
+
 and effector memory CD8
+
 T cells (CD8
+
 TEM) 
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display CD44
high
 CD62L
¯
 phenotype (233). 
 
7. Tumor-induced immunosuppression 
 
In earlier stages of cellular transformation, immunosurveillance can detect and 
eliminate tumor cells. However, with a progressing tumor growth, tumor variants with 
reduced immunogenicity, and/or various acquired mechanisms to corrupt the host 
antitumor response and to escape from the host immune system, arise, survive and 
grow in the host (234-236). As a result, interactions between tumor cells and host 
immune cells in the tumor microenvironment create an immunosuppressive network 
in which CSCs might actively participate in inducing the immunosuppression and 
promoting an evasion from immunosurveillance due to their malignant potential (236). 
Cancer cells display multiple immunosuppressive mechanisms to evade T cell 
responses either by avoiding immune recognition or by disabling effector T cells 
(tumor cells can develop the lack of antigen presentation leading to tolerance or T-cell 
anergy) (123). These include alterations of components of the antigen presentation 
machinery, defects in proximal TCR signaling, secretion of immunosuppressive 
and/or pro-apoptotic factors, activation of negative regulatory pathways, and specific 
recruitment of regulatory cell populations (237), such as regulatory T cells (Tregs) 
(238-240) and myeloid-derived suppressor cells (MDSC) which may secrete 
immunosuppressive factors such as IL-10, TGF-, arginase-1 and nitric oxide (NO). 
Another mechanism which is utilized by tumor cells to block antitumor immunity 
is the induction of the exhausted phenotype of activated CD8
+
 T cells through PD-L1 
(B7-H1 or CD274) expression (216, 241-243). The expression of PD-L1 has been 
reported on solid tumor cells including melanoma cells (123, 244, 245). Moreover, 
murine and human tumor cells up-regulated PD-L1 upon IFN- stimulation, which led 
to the failure of tumor eradication (246, 247). Importantly, the expression of PD-L1 
on leukemia cells has been reported as a marker of tumor dormancy (248, 249). Some 
other molecules such as CTLA-4 (CD152) (250-252), CD39 (ectonucleoside 
triphosphate), CD73 (253-255), and CCR4 (256-259), expressed on human tumor 
cells, including melanoma cells have been documented to impair anti-tumor 
responses. 
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Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a cell surface receptor 
that behaves as a negative regulator of the proliferation and the effector function of T 
cells. Therefore, the negative role of CTLA-4 on T-cell activation contributes to the 
physiologic termination of the immune response. CTLA-4 inhibitory function occurs 
upon interaction with its ligands CD80 (B7.1) and CD86 (B7.2), expressed on APCs, 
resulting in inhibition of IL-2, IFN-, IL-4 cytokines production, IL-2 receptor 
expression and cell cycle progression (252). It has been described that CTLA-4 is 
constitutively expressed on several tumor cell lines including breast, colon, renal, lung, 
ovarian, uterine, bladder carcinoma, neuroblastoma and melanoma and can be used to 
trigger apoptosis upon ligand interaction (252). The chemokine receptor CCR4 is 
preferentially express on certain immune cells and some hematological tumor cells 
(leukemia and lymphoma cells), which play pivotal roles in suppression of host 
immune response. The selective expression of CCR4 on Th2 and Treg cells is 
important in regulating immune balance (256). Tregs preferentially express CCR4 
compared to conventional T cells in both mice and humans (257, 260). The binding of 
CCL17 and CCL22 to CCR4 helps to guide Tregs toward DC. This interaction can 
suppress DC-mediated immune responses (257, 261). Aberrant expression of CCR4 in 
human gastric cancer contributes to tumor-induced immunosuppression (256). 
Another mechanism that is used by tumors to evade immunosurveillance is the 
generation of adenosine within the tumor microenvironment, which potently 
suppresses antitumor T cell responses (259). Adenosine within the tumor is generated 
by CD73, a membrane-bound nucleotidase that is expressed by tumor cells, 
suppressive immune subsets such as Tregs and MDSC and endothelial cells. Recent 
evidence suggests that targeted inhibition of CD73 has the potential to reduce 
tumorigenesis and metastasis, as well as to enhance the potency of T-cell-direct 
therapies (259). As CD73, CD39 is an ecto-enzyme which coordinately works with 
CD73 to degrade ATP leading to the extracellular adenosine generation in the tumor 
microenvironment. Extracellular adenosine promotes tumor growth by limiting 
antitumor T-cell immunity via adenosine receptor signaling (254, 255). 
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8. Ret transgenic mouse spontaneous melanoma model 
 
Conventional mouse melanoma models (e.g., B16) are based on the 
transplantation of tumor cells, in which the natural history of the disease is not 
comparable with the clinical situation In contrast to transplantation models, the 
recently described ret transgenic mouse model showed similarity to human melanoma 
with respect to histopathology and clinical development (232, 262, 263). Mice 
expressing the human ret proto-oncogene under the control of the mouse 
metallothionein-I (MT) promoter-enhancer in melanocytes develop spontaneously 
malignant cutaneous melanoma metastasizing to lymph nodes, lungs, brain, kidney, 
and spleen. This metastatic profile resembles that of human malignant melanoma (262, 
263). Overexpression of Ret kinase is associated with the activation of other kinases 
such as mitogen-activated protein kinase (MAPK) and c-Jun as well as matrix 
metalloproteinases located downstream of the ret kinase (262, 264-266). The 
activation of Ras-Raf pathway induces the degradation of p27. Because p27 cannot 
inhibit the activity of cyclinD1-CDK4 complexes, these complexes are able to 
phosphorylate pRb. Therefore, pRb is completely inactive and E2F transcription 
factor remains active, allowing the progression of the cell-cycle from quiescence to 
the proliferative state (267). Furthermore Raf activates cyclin D1-CDK4 complexes 
which lead to cell proliferation (268, 269). 
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II.  Aims of the study 
 
CSCs could represent disseminated dormant tumor cells without clinical signs of 
tumor progression. Disseminated dormant tumor cells in the bone marrow (BM) of 
mice without macroscopic primary skin tumor could be involved in the maintenance 
of memory CD8
+
 T cells. The objective of this work was to investigate the 
interactions between dormant tumor cells and memory T cells in the bone marrow 
(BM) of ret transgenic mice and to determine whether dormant tumor cells share 
characteristics and properties of CSCs. The following points were addressed: 
a) To examine the expression of putative cancer stem cell markers in primary tumors 
and lymph nodes metastasis. 
b) To test the localization of TRP-2+CD133+ melanoma cells in primary tumors. 
c) To investigate the immunosuppressive, metastatic and angiogenic profile of 
CD133
+
 melanoma cells. 
d) To characterize the dormant state of disseminated TRP-2+CD133+ melanoma in 
the BM. 
e) To detect the frequency of dormant melanoma cells either surrounded by or 
co-localized with memory CD4
+
 T cells and memory CD8
+
 T cells in the BM. 
f) To identify TRP-2-specific and perforin-producing CD8+ T cells co-localized with 
dormant melanoma cells in the BM. 
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III. Materials and methods 
9. Materials 
9.1 Antibodies used for flow cytometry 
 
Specificity Conjugated Clone Isotype Company 
CD133 PerCp-eFluor710 134A rat IgG1, eBioscience 
CD133 PE 134A rat IgG1, eBioscience 
CD133 FITC 134A rat IgG1, eBioscience 
CD133 Alexa Fluor 488 134A rat IgG1, eBioscience 
CD31 PE-Cy7 390 rat IgG2a, eBioscience 
CD31 FITC 390 rat IgG2a, BD 
CD31 APC MEC 13.3 rat IgG2a, BD 
CD45.2 APC-Cy7 104 mouse IgG2a, BD 
CD45.2 PerCpCy5.5 104 mouse IgG2a, BD 
CD45.2 FITC 104 mouse IgG2a, BD 
ret PE 132507 IgG1 R & D Systems 
TRP-2 purified polyclonal IgG Abcam 
CD20 PE AISB12 rat IgG2a eBioscience 
CD24 PE MI/69 rat IgG2b, eBioscience 
CD34 Alexa Fluor 647 RAM34 rat IgG2a, BD 
CD39 PE-Cy7 24DMS1 rat IgG2b, eBioscience 
CD44 PE IM7 rat IgG2b, BD 
CD44 FITC IM7 rat IgG2b, BD 
CD73 FITC AD2 mouse IgG1, eBioscience 
VEGFR2/CD309 PE Avas121 rat IgG2a, BD 
CD152/CTLA-4 PE UC10-4F10-11 armenian hamster 
IgG1, 
BD 
CD166 PE eBioALC48 rat IgG2a, eBioscience 
CD183/CXCR3 APC CXCR3-173 armenian hamster 
IgG 
Biolegend 
CD184/CXCR4 Biotin 2B11/CXCR4 rat IgG2b, BD 
CD194 /CCR4 APC 2G12 armenian hamster 
IgG 
Biolegend 
CD271 FITC MLR-2 IgG2a Stem Cell 
Biotechnologies 
CD271 Alexa Fluor 647 C40-1457 mouse IgG1,κ BD 
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CD274 /PD-L1 APC 10F.9G2 rat IgG2b, Biolegend 
ABCB5 purified polyclonal rabbit anti-mouse Rockland 
Nestin purified -------- rabbit anti-mouse Sigma 
HIF-1α CFS 241812 mouse IgG1 R & D Systems 
HIF-1 α PE 241812 mouse IgG1 R & D Systems 
Fc block 
(CD16/CD32) 
Purified 
 
2.4G2 rat IgG2b, BD 
Anti-biotin PE Streptavidin -------- -------- BD 
anti-rabbit Alexa Fluor 488 -------- -------- Invitrogene 
 
9.2 Antibodies used for immunofluorescence 
 
Specificity Conjugated Specie 
reactivity 
Clone Isotype Company 
CD133 purified rat 
anti-mouse 
134A rat 
IgG1, 
eBioscience 
TRP-2 purified rabbit anti 
mouse 
policlonal --------- Abcam 
H-2k
b
TRP-2180-188 
Dextramer 
R-PE mouse -------- -------- Immudex 
CD31 purified rat 
anti-mouse 
MEC 13.3 IgG2a, BD 
Ki67 Alexa Fluor 
647 
anti-mouse B56 IgG1 BD 
p16 purified mouse 
anti-mouse 
-------- IgG1 Abbiotec 
p27 purified mouse 
anti-mouse 
57/Kipl/p27 IgG1 BD 
PCNA purified mouse 
anti-mouse 
24/PCNA IgG1 BD 
CD4 Alexa Fluor 
647 
rat 
anti-mouse 
RM4-5 IgG2a, Biolegend 
CD8 Alexa Fluor 
647 
rat 
anti-mouse 
53-6.7 IgG2a, Biolegend 
CD44 Alexa Fluor rat IM7 IgG2b, Biolegend 
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488 anti-mouse 
CD45RB FITC rat 
anti-mouse 
C363-16A IgG2a, Biolegend 
Perforin FITC rat 
anti-mouse 
CB5.4 IgG2a Abcam 
IFN- purified rat 
anti-mouse 
R4-6A2 IgG1, eBioscience 
anti-rabbit Alexa Fluor 
488 
goat 
anti-rabbit 
-------- -------- Invitrogene 
anti-rat Alexa Fluor 
555 
goat anti-rat -------- -------- Invitrogene 
anti-rat Alexa Fluor 
594 
goat anti-rat -------- -------- Invitrogene 
anti-rabbit Alexa Fluor 
405 
goat 
anti-rabbit 
-------- -------- Invitrogene 
 
9.3 Chemicals 
 
Component Abbreviation Company Catalog number 
Bovine serum albumin BSA Sigma 7030-50G 
Dimethylsulfoxid DMSO Merck 109678 
Ethylenediaminetetra- 
acetic acid 
EDTA GIBCO 15575-098 
100% acetic acid CH3COOH Merck 100063 
Fetal bovine serum FBS PAN Biotech 3702-P260718 
Phosphate buffered saline PBS PAA H15-002 
Penicillin / Streptomycin P/S PAA P11-010 
Trypan blue solution  Sigma T8154 
Tween20  Sigma P-2287 
Goat serum  GIBCO PCN5000 
Collagenase II  Gibco 1701-015 
Collagenase IV  Gibco 17104-019 
DNAase-I  Sigma 056K7680 
Gelatin  Merck 1.04078.1000 
methanol  Merck  
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Tissue-Tek  Sakura 116600003 
acetone  Merck 1.00014.2511 
Glycine Gly, G Roth 3908.1 
Roswell Park Memorial 
Institute medium 1640 
RPMI-1640 PAA 10 236 276 001 
Fetal calf serum FCS PAA  
goat serum gs PAA  
4',6-Diamidine-2'- 
phenylindole dihydrochloride 
DAPI Roche 10236276001 
Propidium diodide PI BD 51-66221E 
SytoxRed         Invitrogene S34859 
Hoechst 33258 (blue dye)  Sigma 861405 
Superfrost-plus slides Thermo 
scientific 
J1800AMNZ 
Fluoromount-G  SoutherBiotech 0100-01 
 
9.4 Routine laboratory materials, equipment and instruments 
Devices and equipment 
 
Equipment Model Company 
Flow Cytometry FACS Canto II BD 
Fume hood STA 120 1297 Prutscher 
Refrigerator (-80 °C) HeraFreeze Heraeus 
Refrigerator (-20 °C) Premium LiebHerr 
Incubator HeraCell Heraeus 
Inverse microscope  Leica 
Fluoresce microscope DC500 Leica 
Microscope camera  Canon 
Confocal microscope DMRE Leica 
Confocal microscope LSM-710 Carls Zeiss 
Microtome RM 2125 RT Leica 
Microtome water bath HI 1210 Leica 
Microwave oven R-352 Sharp 
pH meter 766 Calimatic 
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Photometer UltroSpec 3100pro Amersham 
Laminar flow cabinet Hera Safe Thermo Electron 
Cooperation 
Container for liquid 
nitrogen 
Isotherm KGW 
Liquid nitrogen tank Biosafe MD Messer 
Timer  Oregon Scientific 
Vortex REAX top Heidolph 
Vortex Vortex Genie 2 Scientific Industries 
Balance BP 3100P Sartorius 
Water bath DC3 HAAKE / GFL 
Centrifuger Labofuge 400R Heraeus 
Centrifuger Biofuge pico Heraeus 
Centrifuger Biofuge primo R Heraeus 
Centrifuger Varifuge K Heraeus 
Centrifuger RT 7 Plus Thermo Electron 
Cooperation 
 
Routine laboratory materials 
 
Material / Instrument Model Company 
Needles 0,4x19 mm Mikrolance BD 
Needles 0,3x13 mm Mikrolance BD 
Cryo tubes Cryos Greiner 
2-20 μl, 20-200 μl, 
200-1000 μl; Pipettes with 
adjustable volumes 
 Rainin 
Coverglass 24 x 24 mm, Roth  
Tubes 15 ml / 50 ml Polypropylen Falcon Falcon 
0.5, 1.5 & 2 ml microtubes  Eppendorf 
1, 5 ml Syringes  BD 
Cell culture plates 96-well-Platte Greiner 
100 μm cell strainer Nylon BD 
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9.5 Buffers 
9.5.1 Buffers for flow cytometry 
 
To prepare single tumor cell suspensions from mLN, we used FACS buffer-1 
which contained 2mM EDTA, and 0.1% BSA in PBS without calcium and magnesium 
(PBS
without Ca/Mg
). FACS buffer-2 consisted of 2mM EDTA, 0.1% BSA, in 1X 
permeabilization buffer (eBioscience Cat. 00-8333). Both FACS buffer-1 and -2 
enable to keep single tumor cell suspensions, avoiding clump formation. We used 
Foxp3 Staining Buffer Set (cat number 00-5523). Fixation /Permeabilization 
Concentrate (Cat. 00-5123). Fixation / Permeabilization diluent (Cat. Nr. 00-5223). 
Permeabilization buffer (10X) (Cat. 00-8333). 
 
9.5.2 Buffers for immunofluorescence 
 
We prepared immunofluorescence buffer (IF-buffer) diluting 0.2% gelatin in PBS. 
IF-buffer-goat serum (IF-gs) consisted of 2% goat serum in IF-buffer. 
 
9.6 ret transgenic spontaneous melanoma mouse model 
 
Mice (C57BL/6 background), which express human ret transgene in melanocytes 
under the control of mouse metallothionein I promoter-enhancer were crossed and 
kept under specific pathogen-free conditions in the animal facility of German Cancer 
Research Center (Heidelberg, Germany). Experiments were performed in accordance 
with government and institute guidelines and regulations. The general performance of 
mice was monitored daily. Spontaneous tumor development was assessed 
macroscopically. 
 
10. Methods 
10.1 Single-cell suspension preparation 
 
Fresh tumors and lymph nodes collected from ret transgenic tumor bearing mice 
were immediately transferred into PBS with calcium and magnesium (PBS with
 Ca/Mg
) 
and briefly stored on ice. After removal of necrotic tissue and fat, tumor biopsies were 
mechanically dissociated mincing with a scalpel into small pieces and enzymatically 
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digested with 1:1 (v/v) of a fresh solution of 0.25% collagenase II, 0.25% collagenase 
IV and 0.05% DNAase-I in PBS
without Ca/Mg
 (this PBS reduces the collagenase activity) 
for 15 min at 37°C (shaking gently every 3 min). Briefly, these two specimens were 
washed with 10 ml of RPMI-10 FCS% and filtrated through 100 μm nylon mesh. 
Lysis buffer of red blood cells was not used. Lysis of red blood cells was made in the 
permeabilization step, in order to preserve cell surface antigens.  
 
10.2 Flow cytometry 
 
Single tumor cell suspensions were fixed and permeabilized with Foxp3 staining 
buffer set (fixation/permeabilization concentrate, and fixation/permeabilization 
diluent) for 30 min at 4°C. Then cell suspension was washed twice with FACS 
buffer-2 and incubated with 1L Fc block /1x106 cells for 20 min at 4°C and stained 
with polyclonal / monoclonal antibodies for 40 min at 4°C. Acquisition was done by 
six-color flow cytometry using a Canto II with FACS-Diva software (Bioscience) and 
dead cell and duplex exclusion based on scatter profile. FlowJo software (Tree Star) 
was used to analyze at least 1X10
6
 events. Data were expressed as dot plots or 
histograms. 
 
10.3 Immunofluorescence 
 
CD133
+
TRP-2
+
 melanoma cells in primary skin tumors, mLN and BM 
 
Primary tumors express melanoma associated antigens like tyrosinase, tyrosinase 
related protein (TRP)-1, TRP-2 and gp100, which can be used for the melanoma 
detection. In this study, CD133
+
TRP-2
+
 melanoma cells were analyzed in primary 
skin tumors and mLN of tumor bearing mice using crysections and triple 
immunofluorescence (IF)-sequential protocol. The tissue specimens were surrounded 
and covered with Tissue-Tek and gradually frozen with isopentan up -80°C (first, 
samples were exposed with isopentan for 10 min at -20°C; second, samples in 
isopentan were placed within liquid nitrogen for 10 min at -150°C; third, samples 
embedded in tissue-Tek were exposed directly to liquid nitrogen for 10 min and 
preserved at -80°C). Consecutive cryostat sections 5 m in thickness were fixed and 
permeabilized with methanol-acetone (7:3) for 10 min at -20°C, incubated with 0.1M 
Materials and methods 
42 
of glycine in PBS for 30 minutes at 4°C and first blocking step with 10% goat serum 
in IF-buffer was done for 30 min at 37°C. The samples were washed twice with 
IF-buffer and stained with first primary monoclonal rat anti-mouse antibodies against 
CD133 (12 g/ml in IF-gs) overnight at 4°C, washed 5 times with IF-buffer and 
incubated with first secondary goat anti-rat antibodies labeled with Alexa-Fluor 594 
(1:500 in IF-gs) for 1h at 4°C. The samples were washed 4 times with IF-buffer and 
second blocking step with 10% goat serum in IF-buffer was done. 
 For the identification of TRP-2, the samples were incubated with second primary 
polyclonal rabbit anti-mouse antibodies against TRP-2 (1:2000 in IF-gs) for 1h at 4°C, 
washed 4 times with IF-buffer and incubated with second secondary goat anti-rabbit 
antibodies labeled with Alexa-Flour-488 (1:1000 in IF-gs) for 1h at 4°C. The samples 
were washed 4 times with IF-buffer and nuclei were stained with 
4,6-diamidino-2-phenylindole (DAPI) (1:3000 in PBS) for 3 min at room temperate 
(RT). As control we incubated the samples with first secondary goat anti-rat 
antibodies labeled with Alexa-Fluor 594 and second secondary goat anti-rabbit 
antibodies labeled with Alexa-Flour-488 as well as specimens of healthy skin and 
lymph nodes from wild type mice. Confocal microscopy was acquired using a 
confocal laser scanning microscope LSM-710 (Carl-Zeiss, Jena, Germany) under a 40 
times oil-immersion objective and data were analyzed by ZEN software (Carl-Zeiss, 
Jena, Germany).  
BM specimens were isolated from femurs by aspiration and 1x10
5
 BM cells 
/sample were prepared using cytospin technique. The specimens were fixed and 
permeabilized with methanol-acetone (7:3) for 10 min at -20°C. For CD133, TRP-2 
and nuclei staining, we performed triple IF-sequential protocol as well, such as 
described above. We analyzed in total 10
6
 BM cells per mouse from 20 mice without 
macroscopic skin tumors and 20 mice bearing macroscopic tumors. 
 
Cell cycle status of CD133
+
TRP-2
+
 melanoma cells in the BM 
 
BM samples were isolated from femurs by mechanical dissection, mounted on 
glasses through smear technique, fixed and permeabilized with methanol-acetone (7:3) 
for 10 min at -20°C. For CD133 and TRP-2 staining, we performed triple 
IF-sequential protocol as well, such as described above, with the exception of nuclei 
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which were stained with propidium iodide (1:1000 in PBS) for 10 min at the end of 
the whole staining. For the analysis of cyclin-dependent kinase inhibitors (CDKI) the 
following primary antibodies were used: mouse anti-p16 (1:50 in IF-gs) and mouse 
anti-p27 (1:100 in IF-gs). As indicators of cell cycle progression, the primary mouse 
antibodies against PCNA (1:100 in IF-gs), and mouse antibody anti-Ki67 labeled with 
Alexa Fluor 647 (1:10 in IF-gs). Isotype-matched irrelevant antibodies served as 
negative controls. For the identification of the antibodies mouse anti-p16, mouse 
anti-p27 and mouse anti-PCNA we used the secondary antibodies goat anti-mouse 
labeled with Alexa Fluor 405 (1:500 in IF-gs). The table 1 illustrates the panel of dyes 
used. 
 
Table 1. Immunoflorescence staining for the determination of the dormancy status of 
CD133
+
TRP-2
+
 melanoma cells in the BM of ret transgenic mice. 
 
 
Blood vessels staining in primary tumors 
 
To analyze the vascularization in primary skin tumors of ret transgenic mice, we 
performed cryosections and IF staining. Cryosections were prepared, fixed, 
permeabilized and preserved as described above. Then, the specimens were incubated 
with 0.1M of glycine in PBS for 30 minutes at 4°C and blocked with 10% goat serum 
in IF-buffer for 30 min at 37°C. The samples were washed twice with IF-buffer and 
stained with primary monoclonal rat anti-mouse antibodies against CD31 (1:50 in 
IF-gs) for 2h at 4°C, washed 5 times with IF-buffer and incubated with secondary goat 
anti-rat antibodies labeled with Alexa-Fluor 555 (1:250 in IF-gs) for 1.5h at 4°C. The 
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samples were washed 4 times with IF-buffer and nuclei were stained with DAPI 
(1:3000 in PBS) for 3 min at RT. As control we incubated the samples with secondary 
goat anti-rat antibodies labeled with Alexa-Fluor 555 as well as specimens of healthy 
skin from wild type mice. 
 
Co-localization of CD133
+
 / CD133¯ tumor cells with T cells in the BM 
 
To study the interaction between dormant tumor cells and memory T cells in the 
BM of ret transgenic mice, we used smear technique and IF staining. For CD133 and 
TRP-2 staining, we performed triple IF-sequential protocol such as described above, 
with the exception of nuclei was not stained and the secondary goat anti-rabbit 
antibodies labeled with Alexa Fluor 405 were used to detect antibodies rabbit 
anti-TRP-2. Third blocking step with 10% goat serum in IF-buffer was included and 
the samples were washed 3 times with IF-buffer. We analyzed smears from BM of 
mice without and with macroscopic primary tumors. Then, the specimens were 
stained using a multicolor IF protocol for the identification of memory T cells as 
described below. 
 
Memory CD4
+
 T cells 
 
For the identification of memory CD4
+
 T cells, the samples were incubated with 
rat monoclonal antibodies against CD45RB labeled with FITC (1:250 in IF-gs) and rat 
monoclonal antibodies against CD4 labeled with Alexa-Fluor-647 (1:250 in IF-gs) for 
1h at RT. 
 
Memory CD8
+
 T cells  
 
For the identification of memory CD8
+
 T cells, the samples were incubated with 
rat monoclonal antibodies against CD44 labeled with Alexa-Fluor-488 (1:250 in IF-gs) 
and rat monoclonal antibodies against CD8
+
 labeled with Alexa-Fluor-647 (1:250 in 
IF-gs) for 1h at 4°C (Table 2A). 
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TRP-2-specific-, perforin-producing CD8
+
 T cells 
 
The samples were incubated with rat monoclonal antibodies against CD8
+
 labeled 
with Alexa-Fluor-647 (1:250 in IF-gs), rat monoclonal antibodies against perforin 
labeled with FITC (1:500 in IF-gs) and H-2K
b
-TRP-2180-188 Dextramer labeled with 
R-PE (Table 2B). 
 
IFN--, perforin-producing CD8+ T cells  
 
The samples were incubated with rat monoclonal antibodies against IFN- (1:250 
in IF-gs) for 1h at 4°C, washed 4 times with IF-buffer and stained with secondary goat 
anti-rat antibodies labeled with Alexa-Flour-555 (1:500 in IF-gs) for 1h at 4°C. Briefly, 
the samples were washed 4 times with IF-buffer and stained with rat monoclonal 
antibodies against CD8
+
 labeled with Alexa-Fluor-647 (1:250 in IF-gs), and rat 
monoclonal antibodies against perforin labeled with FITC (1:250 in IF-gs) (Table 2C 
and 2D). 
 
Experimental design 
 
Table 2. Immunoflorescence staining for memory CD4
+
 and memory CD8
+
 T cells. 
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11. Statistical analysis 
 
We used software Flowjo (Version 7.2.4), Tree Star, Inc., Ashland, USA. All data 
are shown as mean ± SEM for the indicated number of independent experiments. 
Results were assessed with a Student´s t test and Mann-Whitney U test. Statistical 
analyses were performed using Graph-Pad Prism software (San Diego, USA). All 
statistical tests were two-sided. A value of p < 0.05 was considered statistically 
significant. 
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IntroductionResults 
IV. Results 
 
There is an intensive debate on protocols for preparing single cell suspensions 
from primary tumor specimens for flow cytometric analysis of CSCs (103, 125, 270). 
A great majority of routine procedures consist of mechanical dissociation followed by 
enzymatic disaggregation where tumor specimens are incubated longer at 37°C 
(overnight as maximum to 0.75-2 h as minimum). Most of the enzymatic protocols 
use trypsin, which is tremendously aggressive because cleave proteins on the cells 
surface, removing the antigens that are under investigation (124, 163). Although other 
protocols use collagenase II and collagenase IV which are much less aggressive, 
tumor specimens are incubated longer (0.75-2 h) or followed by short incubation with 
low concentration of trypsin (124). Hence reliable methods are required for avoid the 
excision of antigens used as CSC markers. We applied a gentle protocol to prepare 
single tumor cell suspensions by incubating tumor tissues with collagenase II, 
collagenase IV and DNAase for a brief period of incubation at 37°C (15 minutes) 
shaking gently to ensure the preservation of antigens on the cell surface. Applying this 
protocol we obtained detection of CSCs and a higher index of live cells (more than 
95%). 
We investigated cancer stem-like cells in ret transgenic mice using CD133 
(Prominin-1), which has been widely shown to be a marker of cancer stem-like cells 
in various solid tumors, including melanomas (168-181). Freshly isolated cells from 
primary skin tumors and mLN were analyzed by FACS staining: leukocytes and 
endothelial cells were excluded using CD45.2 and CD31 staining respectively. Duplex 
exclusion and dead cells were based on scatter profile. Tumor cells where stained with 
antibodies for TRP-2, CD133, and Ki67 (proliferation marker). Fig. 1 and 2 show the 
FACS staining strategy for the analysis of CD133
+
Ki67
+
 tumor cells in primary skin 
tumors and mLN, respectively. 
The data revealed that mLN contained almost 5-fold higher numbers of 
TRP-2
+
CD133
+ 
melanoma cells in comparison with primary skin tumors (Fig 3A). We 
also found that mice with larger primary tumors have more TRP-2
+
CD133
+
 melanoma 
cells both in tumors and mLN than mice with smaller primary tumors (Fig. 3B, C). 
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Figure 1. CD133
+
 expression in primary tumors. Single-cell suspensions prepared from 
tumors of ret transgenic mice were stained with antibodies for CD45.2, CD31, TRP-2, CD133 
and Ki67 followed by flow cytometry. (A) Duplex and dead cells were excluded based on 
scatter profile, then leukocytes and endothelial cells were excluded using CD45.2 and CD31 
markers respectively. (B) Tumor cells were gated based on TRP-2
+
 cells, TRP-2
+
CD133
+
 
cells and TRP-2
+
CD133
+
Ki67
+
 subpopulations. The fluorescence minus one (FMO) controls 
were made for all dyes. Representative dot plots are shown. Tu = primary tumor. The red 
arrows indicate the flow of the dot plots. 
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Figure 2. CD133
+ 
expression in metastatic lymph nodes. Single cell suspensions prepared 
from tumors of ret transgenic mice were stained with antibodies for CD45.2, CD31, TRP-2, 
CD133 and Ki67 followed by flow cytometry. (A) Duplex and dead cells were excluded 
based on scatter profile, then leukocytes and endothelial cells were excluded using CD45.2 
und CD31 markers respectively. (B) Tumor cells were gated based on TRP-2
+
 cells, 
TRP-2
+
CD133
+
 cells and TRP-2
+
CD133
+
Ki67
+
 subpopulations. The fluorescence minus one 
(FMO) controls were made for all dyes. Representative dot plots are shown. mLN= metastatic 
lymph nodes. The red arrows indicate the flow of the dot plots. 
 
12. CD133+ melanoma cells are in a dormant state in larger primary skin tumors 
 
It has been reported that in melanoma patients treated with chemo- and 
radiotherapy, the emersion of tumors from residual tumor cells, which survived 
long-term in a dormant state led to tumor relapse (26, 190). We assumed that dormant 
tumor cells may share characteristics and properties with CSCs. To investigate the 
dormancy status of CD133+  melanoma cells, the proliferative marker Ki67 was used 
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to distinguish between proliferating and quiescent (dormant) melanoma cells. We 
found that CD133+  melanoma cells from primary and mLN had an equal rate of 
proliferation (Fig. 3D). Interestingly, the progression of primary tumors was 
demonstrated to be correlated with a reduced amount of CD133+  melanoma cells in 
proliferative state (checked by the expression of Ki67) (Fig. 3E). In contrast, CD133+  
melanoma cells in mLN from mice with larger primary tumors were highly 
proliferating (Fig. 3F). We conclude that CD133 is expressed by a fraction of TRP-2+  
melanoma cells (less than 1.5 %) and their dormant state is dependent on the weight 
of primary tumors. 
 
 
Figure 3. CD133
+ expression in ret transgenic mice. Single-cell suspensions prepared from 
freshly isolated primary tumors and mLN of ret transgenic mice were stained with antibodies 
for CD45.2, CD31, TRP-2, CD133, and Ki67 followed by flow cytometry. Gating strategy 
was done as described in figures 1 and 2. (A) CD133
+
 melanoma cell numbers in primary 
tumors (Tu) compared to mLN. The percentage of CD133
+
 melanoma cells was plotted 
against tumor weights in (B) primary tumors and (C) mLN. (D) CD133
+
KI67
+
 melanoma cell 
numbers in primary tumors (Tu) compared to mLN. The percentage of CD133
+
KI67
+
 
melanoma cells was plotted against tumor weights in (E) primary tumors and (F) mLN. ns= 
not statistically significant. 
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13. CD133+ melanoma cells are located in peripheral areas in primary tumors 
 
We performed serial cryosections of primary tumors followed of 
immunofluorescence staining for TRP-2, CD133, Ki67 and DAPI. We observed that 
CD133+  melanoma cells form clusters and seem to be predominantly located in the 
peripheral tumor areas (Fig. 4). 
 
Figure 4. Localization of CD133+melanoma cells in primary tumors of ret transgenic 
mice. Consecutive cryosections of tumors were stained with antibodies for TRP-2, CD133, 
and Ki67 and counterstained with DAPI. (A) Tumor section showing the areas (white squares) 
where CD133+melanoma cells were found. (B, C) CD133 positive cells (red), Ki67 positive 
cells (gray), and nuclei (blue). Merge showing the low rate of proliferation of CD133
+
 
melanoma cells. 
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14. CD133+ melanoma cells seem are localized in aberrant vascularized areas 
 
Neovascularization is critical for the tumor optimal growth, cell survival and 
efficient tumor dissemination (271, 272). CSCs may create the niche necessary for the 
maintenance of tumor cells (273, 274). Aberrant architecture of blood vessels may be 
an indicator of tumorigenicity (271, 272). To investigate the structural distribution of 
blood vessels, especially in areas where CD133+  melanoma cells are localized, we 
performed the IF staining of primary tumors using antibodies for CD31 to visualize 
the tumor vascularization. We found that aberrant blood vessels were variable in size, 
shape and branching pattern, and were not organized in conventional hierarchy of 
arterioles, capillaries and venules. These blood vessels have a predominant 
distribution in peripheral areas of tumors (Fig. 5A-C). These areas might be the niche 
for CD133+  melanoma cells within the tumor. Further experiments are needed to 
confirm these observations. 
 
 
  
 
Figure 5. Distribution of endothelial 
cells in primary tumors. Consecutive 
cryosections of tumors were stained with 
antibodies for CD31 (orange) and 
counterstained with DAPI (blue). (A) 
Tumor section showing one tumor sphere 
containing blood vessels. (B) Detail view 
of vascularized areas (green square). (C) 
Distribution of tumor blood vessels. 
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15. HIF-1 and CD271 expression in CD133+ melanoma cells 
 
It has been reported that restricted oxygen conditions increase the CSC fraction 
and promote acquisition of a stem-like state (148). CSCs might critically be 
dependent on hypoxia-inducible factor 1 (HIF-1) for survival, self-renewal and 
tumor growth (148, 149). To examine the expression of HIF-1, single tumor cell 
suspensions isolated from primary skin tumors and mLN were analyzed by FACS 
staining (Fig. 6). The data revealed that mLN nodes contain elevated numbers of 
TRP-2
+
CD133
+
HIF-1+ melanoma cells in comparison with primary tumors (Fig. 
7A). We observed that larger primary tumors had the tendency to contain higher 
numbers of TRP-2
+
CD133
+
HIF-1+ melanoma cells (Fig. 7B), whereas the frequency 
of these cells was decreased in mLN from animals with larger tumors (Fig. 7C). 
Interestingly, TRP-2
+
CD133
+
HIF-1+ melanoma cells had an elevated capacity to 
proliferative in primary tumors in comparison with those in mLN (Fig. 7 D). These 
findings suggest that HIF-1 plays a crucial role in the maintenance of CD133+  
melanoma cells at the beginning of the tumor formation. In fact, we observed an 
elevated number of TRP-2
+
CD133
+
HIF-1+ melanoma cells in smaller primary 
tumors and mLN with an increased rate of proliferation (Fig. 7 E, F). 
Figure 6. HIF-1 expression in 
CD133
+ 
melanoma cells. Freshly 
isolated melanoma cells from 
primary tumors and mLN were 
evaluated by flow cytometry. 
Endothelial cells and leukocytes were 
excluded using CD31 and CD45.2 
markers respectively and HIF-1+ 
expression on TRP-2
+
CD133
+
 tumor 
cells and Ki67 expression on 
TRP-2
+
CD133
+
HIF-1+ cells were 
analyzed in (A) primary tumors and 
(B) mLN. Representative dot plots 
are shown. 
 
Results 
54 
 
 
Figure 7. HIF-1 expression in CD133+ melanoma cells. Freshly isolated melanoma cells 
from primary tumors and mLN were evaluated by flow cytometry. Endothelial cells and 
leukocytes were excluded using CD31 and CD45.2 markers respectively and HIF-1+ 
expression on TRP-2
+
CD133
+
 tumor cells and Ki67 expression on TRP-2
+
CD133
+
HIF-1+ 
cells were analyzed. Gating strategy was done as described in figure 6. (A) CD133
+
HIF-1+ 
melanoma cell numbers in primary tumors (Tu) compared to mLN. The percentage of 
TRP-2
+
CD133
+
 HIF-1+ melanoma cells was plotted against tumor weights in (B) primary 
tumors and (C) mLN. (D) TRP-2
+
CD133
+
HIF-1+KI67+ melanoma cells in primary tumors 
(Tu) compared to mLN. The percentage of TRP-2
+
CD133
+
HIF-1+KI67+ melanoma cells was 
plotted against tumor weights in (E) primary tumors and (F) mLN. 
 
CD271 has been recently described as a melanoma stem cell marker with an 
increased tumor-initiating capacity as compared with CD271¯ tumor cells (124). 
CD271 melanoma cells have shown multipotency, self-renewal capacity, to be 
maintained in several rounds of serial retransplantations and higher metastatic 
potential (125). To address the question whether the expression of CD271 in 
TRP-2
+
CD133
+ 
melanoma cells is dependent on tumor progression, melanoma cells 
Results 
55 
from primary tumors and mLN were stained with antibodies for CD271, CD133, Ki67 
and TRP-2 followed by flow cytometry (Fig. 8). Lymph node metastasis displayed a 
tendency to elevate the numbers of CD133
+
CD271
+
 cells in comparison to primary 
tumors (Fig. 9A). We did not observed any correlation of tumor progression for 
TRP-2
+
CD133
+
CD271
+ 
cell numbers in primary tumors and mLN (Fig. 9B, C). 
Primary tumors were found to have an elevated number of TRP-2
+
CD133
+
CD271
+
 
melanoma cells in the proliferative state in comparison to mLN (Fig. 9D). We 
observed that TRP-2
+
CD133
+
CD271
+
 melanoma cells exhibit a stable rate of 
proliferation in both early and advanced stages of tumor progression in primary 
tumors (Fig. 9E). In addition, many TRP-2
+
CD133
+
CD271
+ 
melanoma cells exhibit a 
pronounced proliferative capacity in early stages of tumor growth in mLN (Fig 9F). 
 
 
Figure 8. CD271 expression on 
CD133
+ 
melanoma cells. Freshly 
isolated melanoma cells from 
primary tumors and mLN were 
evaluated by flow cytometry. 
Endothelial cells and leukocytes 
were excluded using CD31 and 
CD45.2 markers respectively and 
CD271 expression on 
TRP-2
+
CD133
+
 tumor cells and 
Ki67 expression on 
TRP-2
+
CD133
+
CD271
+
 cells were 
analyzed in (A) primary tumors and 
(B) mLN. Representative dot plots 
are shown. 
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Figure 9. CD271 expression on CD133
+
melanoma cells. Freshly isolated melanoma cells 
from primary tumors and mLN were evaluated by flow cytometry. Endothelial cells and 
leukocytes were excluded using CD31 and CD45.2 markers respectively and CD271 
expression on TRP-2
+
CD133
+
 tumor cells and Ki67 expression on TRP-2
+
CD133
+
CD271
+
 
were analyzed. Gating strategy was done as described in the figure 8. (A) CD133
+
CD271
+
 
melanoma cell numbers in primary tumors (Tu) compared with mLN. The percentage of 
TRP-2
+
CD133
+
 CD271
+ 
melanoma cells was plotted against tumor weights in (B) primary 
tumors and (C) mLN. (D) TRP-2
+
CD133
+
CD271
+
Ki67
+
 melanoma cell numbers in primary 
tumors (Tu) compared to mLN. The percentage of TRP-2
+
CD133
+
CD271
+
KI67
+
 melanoma 
cells was plotted against tumor weights in (E) primary tumors and (F) mLN. ns= not 
statistically significant. 
 
16. CD133+ melanoma cells express PD-L1, CTLA-4, CD39, CCR4, VEGF-R2, 
CXCR3, CXCR4, and CD34 
 
PD-L1 (CD274), CTLA-4 (CD152), CD39, CD73, and CCR4, have been 
documented as immunosuppressive factors expressed on tumor cells (123, 244, 245, 
250-259), CXCR3 and CXCR4 have been described as master regulators of 
metastases (136, 137), whereas VEGFR is an essential factor to promote angiogenesis 
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(138, 139). CD34 was reported as a murine melanocyte stem cell maker (82). To 
examine the immunosuppressive, metastatic and angiogenic as well as the melanocyte 
stemness profile of CD133
+
 melanoma cells, primary tumors and mLN were stained 
with respective antibodies against their antigens (Fig. 10) followed by flow cytometry. 
 
 
Results 
58 
 
Figure 10. Phenotypic analysis of CD133
+
 melanoma cells. Freshly isolated melanoma 
cells from primary tumors (Tu) and mLN were evaluated by flow cytometry. (A) Endothelial 
cells and leukocytes were excluded using antibodies for CD31 and CD45.2 respectively. 
Specimens were stained with antibodies for TRP-2. Then, PD-L1, CTL-4, CD39, CCR4, 
VEGFR2, CXCR3, CXCR4, and CD34 expression was analyzed on CD133
+
 and CD133¯ 
melanoma cells. Representative histograms of cells from primary tumors are shown. (A) 
Melanocyte stemness marker, (B) metastasis-related markers and (C) 
immunosuppression-related markers. FMO CD133 = fluorescence minus one for CD133. 
CD133¯= CD133¯melanoma cells. CD133
+
 = CD133
+ 
melanoma cells. 
 
 
The data revealed that almost all studied markers were expressed on CD133
+
 
melanoma cells much stronger than on CD133¯ tumor cells (Fig. 10). CD73 
expression was absent in both CD133
+
 and CD133¯ tumor cells. In contrast, CXCR4 
and CCR4 showed similar expression on both tumor cell subsets from primary tumors, 
whereas CXCR3 showed similar expression on both subsets from mLN. We 
concluded that CD133
+
 melanoma cells exhibit immunosuppressive, metastatic, 
angiogenic and melanocyte stemness profile which might promote the establishment 
of tumor-initiating cells in primary tumors, their progression and metastasis to lymph 
nodes and distant organs. 
 
17. Analysis of HIF-1α and CD271 expression on melanoma cells 
 
Since HIF-1 and CD271 are important markers of CSCs and tumor dormancy, 
we studied their expression on melanoma cells from transgenic mice. We stained 
single tumor cell suspensions with antibodies for HIF-1, CD271, CD133, TRP-2, 
CD31, and CD45.2 followed by flow cytometry (Fig. 11). We found that mLN 
contained higher frequencies of TRP-2
+
HIF-1+ melanoma cells than primary tumors 
(Fig. 12A). Larger primary tumors contain a tendency to increase the numbers of 
TRP-2
+
HIF-1+ melanoma cells in primary tumors (Fig. 12B), but a tendency to 
diminish the numbers of TRP-2
+
HIF-1+ melanoma cells in mLN (fig. 12C). 
Cumulative data shown that although TRP-2
+
HIF-1+ melanoma cells both in primary 
tumors and mLN had a similar rate of proliferation (Fig. 12D), we observed a higher 
rate of proliferation of TRP-2
+
HIF-1+ melanoma cells in early stages of tumor 
development both in primary tumors and mLN (Fig. 12E, F). 
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Figure 11. HIF-1 expression on 
melanoma cells. Freshly isolated 
melanoma cells from primary 
tumors and mLN were evaluated by 
flow cytometry. Endothelial cells 
and leukocytes were excluded using 
CD31 and CD45.2 markers 
respectively and HIF-1 expression 
on TRP-2
+ 
tumor cells and Ki67 
expression on TRP-2
+
HIF-1  
tumor cells were analyzed in (A) 
primary tumors and (B) mLN. 
Representative dot plots are shown. 
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Figure 12. HIF-1 expression on melanoma cells. Freshly isolated melanoma cells from 
primary tumors and mLN were evaluated by flow cytometry. Endothelial cells and leukocytes 
were excluded using CD31 and CD45.2 markers respectively and HIF-1 expression on 
TRP-2
+
 tumor cells and Ki67 expression on TRP-2
+
HIF-1+ were analyzed. Gating strategy 
was done as described in the figure 11. (A) HIF-1+ melanoma cell numbers in primary 
tumors (Tu) compared to (mLN. The percentage of TRP-2
+
HIF-1+ melanoma cells was 
plotted against tumor weights in (B) primary tumors and (C) mLN. (D) TRP-2
+
HIF-1+Ki67+ 
melanoma cell numbers in primary tumors (Tu) compared to mLN. The percentage of 
TRP-2
+
HIF-1+Ki67+ melanoma cells was plotted against tumor weights in (E) primary 
tumors and (F) mLN. ns= not statistically significant. 
 
Analyzing CD271 expression (Fig. 13A), we found that mLN have elevated 
numbers of TRP-2
+
CD271
+
 melanoma cells in comparison with primary tumors (Fig. 
113B). Larger primary tumors contain elevated numbers of TRP-2
+
CD271
+
 melanoma 
cells in primary tumors (Fig. 13C), but a tendency to reduce the numbers of 
TRP-2
+
CD271
+
 melanoma cells in mLN (Fig. 13D). Similar amounts of 
TRP-2
+
CD271
+
 melanoma cells shown to be in proliferative phase both in primary 
tumors and mLN (Fig. 13E). Interestingly the proliferation of these cells was 
significantly lower in advanced primary tumors (Fig. 13F). In addition, CD271
+ 
melanoma cells in mLN displayed a strong tendency to diminish their proliferation 
rate in mice with larger primary tumors (Fig. 13G). 
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Figure 13. CD271 expression on melanoma cells. Freshly isolated melanoma cells from 
primary tumors and mLN were evaluated by flow cytometry. Endothelial cells and leukocytes 
were excluded using CD31 and CD45.2 markers respectively and CD271 expression on 
TRP-2
+
 tumor cells and Ki67 expression on TRP-2
+
CD271
+
 were analyzed in (A) primary 
tumors and mLN. Representative dot plot is shown. (B) CD271
+ 
melanoma cell number in 
primary tumors (Tu) compared to mLN. The percentage of TRP-2
+
CD271
+ 
melanoma cells 
was plotted against tumor weights in (C) primary tumors and (D) mLN. (E) 
TRP-2
+
CD271
+
Ki67
+
 melanoma cell numbers in primary tumors (Tu) and mLN. The 
percentage of TRP-2
+
CD271
+
KI67
+
 melanoma cells was plotted against tumor weights in (F) 
primary tumors and (G) mLN. 
 
18. Analysis of other potential cancer stem cell markers 
 
Next we examined the expression of other potential melanoma stem cell markers 
such as CD20, CD24, CD34, CD44, CD166, nestin and multidrug resistant marker 
ABCB5, in primary skin tumors and mLN by flow cytometry (Fig. 14). We found that 
primary skin tumor cells had a higher proportion of CD20+  tumor cells in comparison 
with mLN. Concerning other CSC makers, we found that nestin was constitutively 
expressed on most melanoma cells, whereas the multidrug resistance marker ABCB5 
was expressed on around 90% melanoma cells. There were significantly more 
ABCB5+  melanoma cells in primary tumors than those in mLN. The expression of 
CD166 and CD34 was detected in small amounts of cells in primary tumor and mLN 
(less than 2.5%). 
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Figure 14. Analysis of other potential melanoma stem cell markers. Freshly isolated 
primary tumor cells (Tu) and mLN were evaluated by flow cytometry. Endothelial cells and 
leukocytes were excluded using CD31 and CD45.2 markers respectively and different cancer 
stem cell markers were analyzed. (A) CD20, (B) CD24, (C) CD34, (D) nestin, (E) ABCB5, 
(F) CD166, and (G) CD34. ns = not statistically significant. 
 
19. BM contains disseminated melanoma cells 
 
In this study, TRP-2
+
CD133+  expressing cells were analyzed in the BM of tumor 
bearing mice by double and triple immunofluorescence (IF) protocol. We analyzed 
10
6
 BM cells per mouse from 20 mice without macroscopic tumors (Fig. 15A, B) and 
20 mice bearing macroscopic tumors (Fig. 15C-D). We found that tumor bearing mice 
had more TRP-2+  melanoma cells than mice without macroscopic primary skin 
tumors (Fig. 15E). The majority of TRP-2
+
 melanoma cells were in a dormant state 
(Ki67¯) (Fig. 15F). BM cells from wild type (WT) mice were used as positive control 
for the Ki67 staining (Fig. 15F). 
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Figure 15. Disseminated 
melanoma cells in the BM of 
ret transgenic mice. TRP2+  
melanoma cells in the BM of 
mice without macroscopic 
primary tumors (A-B) and 
tumor bearing mice (C-D) 
analyzed by  IF staining. (E) 
Total amount of TRP-2
+
 
melanoma cells in mice 
without macroscopic primary 
tumors (Tg) and tumor bearing 
mice (Tu). (F) TRP-2
+
 cells 
are mostly in a dormant state 
by their negative expression of 
Ki67. WT= Ki67
+
 BM cells 
from wild type mice. 
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We identified TRP-2+CD133+  melanoma cells in mice without macroscopic 
primary tumors (Fig. 16A, B) and tumor bearing mice (Fig. 16C, D). We analyzed 10
6
 
BM cells per mouse from 20 mice without macroscopic tumors and 20 mice bearing 
macroscopic tumors and found that only 40% of mice without macroscopic tumors 
contained TRP-2+CD133+  melanoma cells in the BM. In contrast, all 20 tumor 
bearing mice contained TRP-2+CD133+  melanoma cells. TRP-2+CD133+  melanoma 
cells were detected in 2 out of 712 (0.238%) and 4 out of 1285 (0.311%) disseminated 
melanoma cells in the BM of transgenic mice without and with macroscopic tumors, 
respectively (Fig. 16E and Table 3). BM cells from wild type (WT) mice were used as 
positive control for the CD133 staining (Fig. 16F, G). Therefore, we did not observe 
any differences in the frequency of TRP-2+CD133+  melanoma cells in the BM of ret 
transgenic mice as compared to that in mLN or primary skin tumors. 
 
 
A A 
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Figure 16. Disseminated melanoma cells in the BM of ret transgenic mice. Identification 
of TRP2
+
CD133
+
 melanoma cells in the BM of transgenic mice (A-B) without macroscopic 
tumors or (C-D) bearing macroscopic tumors by IF staining. (E) Frequency of TRP2
+
CD133
+ 
tumor cells in 10
6
 BM cells in mice without macroscopic tumors (tumor free) and mice with 
macroscopic tumors (Tumor). All the pictures were done on Leica Microscope using IF lamp. 
(F) Flow cytometric analysis of CD133 expression on BM cells from wild type mouse and (G) 
using Carl-Zeiss 710 confocal microscope. CD133 (red), nuclei (blue). AF =alexa-fluor. 
 
 
 
 
 
 
 
Results 
66 
 
Table 3. Amount of TRP-2
+
CD133
+
 melanoma cells and TRP-2
+
 melanoma cells in the BM of mice 
without visible primary skin tumors and mice with visible primary skin tumor. 
 
 
To study a possible dormancy state of melanoma cells in the BM of ret transgenic 
mice, we checked nuclear Ki67 expression which is an indicator of cell proliferation, 
in mice with and without primary visible skin tumors (Fig. 17). We observed that 
disseminated TRP-2
+
CD133
+
 melanoma stem-like cells are in a dormant state by their 
negative expression of Ki67 in the BM of mice without and with primary tumors (Fig. 
17B). As controlled, we used BM cells from wild type mouse (WT) (Fig. 17A). 
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To corroborate the dormancy state of melanoma cells in the BM of ret transgenic 
mice, we checked several markers involved in the cell division such as p16, and p27, 
which have been described as cyclin-dependent kinase inhibitors (CDKI). In addition, 
the proliferating cell nuclear antigen (PCNA) and the Ki67 marker were analyzed (Fig. 
18). Whereas melanoma cells failed to express PCNA (Fig. 18A), they were found to 
be positive for p16 and p27 (Fig. 18B, C). We conclude that TRP-2+CD133+ 
melanoma stem-like cells are in a dormant state in the BM and present an aberrant 
expression of Ki67, p16 and p27.  
Figure 17. Disseminated 
dormant melanoma cells in the 
BM of ret transgenic mice. (A) 
CD133 expression on BM cells 
from wild type mouse (WT). (B) 
TRP-2
+
CD133
+ 
melanoma cells in 
the BM of tumor bearing mice 
(Tu). Both CD133
+
 BM cells and 
TRP-2
+
CD133
+
 melanoma cell 
are in a dormant state by their 
negative expression of Ki67. BM 
specimens prepared using 
cytospin and IF staining. Samples 
analyzed with a Carl-Zeiss 
confocal microscope LSM-710. 
CD133 (red), TRP-2 (green), 
Ki67 (pink), nuclei (blue). 
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Figure 18. Expression of dormancy markers in disseminated BM tumor cells in mice 
without macroscopic skin tumors. Immunofluorescence staining for the analysis of (A) 
PCNA, (B) p16+ , and (C) p27+  on CD133
+
 (orange), Ki67 ¯
/cyto
 (pink) melanoma cells. PI = 
propidium iodide. 
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To address the interaction between dormant tumor cells and memory T cells in the 
BM of ret transgenic mice, we analyzed smears from the BM of mice without visible 
skin tumors and with macroscopic tumors (Fig. 19 and 20). 
 
            
 
Figure 19. Memory CD8
+ 
T cells co-localized with TRP-2
+
 cells in the BM of mice 
without macroscopic tumors. Smear technique and multicolor IF staining was performed to 
analyze TRP-2 (blue), CD44 (green), CD133 (red) and CD8
+
 (pink) molecules. The white 
squares show the place of interaction between CD8
+
 T cells and TRP-2
+ 
cells.  
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Figure 20. Memory CD8
+
 T cells co-localized with TRP-2
+
 cells in the BM of tumor 
bearing mice. Smear technique and multicolor IF staining was performed to analyze TRP-2 
(blue), CD44 (green), CD133 (red) and CD8 (pink) molecules. The white squares show the 
place of interaction between CD8
+
 T cells and TRP-2
+ 
cells.  
 
We found that memory CD8+T cells (CD8+CD44
high
) were co-localized with 
TRP-2+  melanoma cells not only in tumor bearing mice (Fig. 20) but also in mice 
without macroscopic tumor (Fig. 19). Importantly, the proportion of memory CD8
+
 T 
cells interacting with TRP-2
+
 melanoma cells was around 15% out of total memory 
CD8
+
 T cells. However, we did not detect any co-localization of memory CD8
+
 T 
cells with disseminated TRP-2
+
CD133
+
 melanoma cells in the BM of both mice 
without visible primary tumors and tumor bearing mice (n=8). Moreover, we found 
that also memory CD4
+
 T cells (CD4+CD45RB
¯
) had a direct contact with TRP-2
+
 
melanoma cells but not with TRP-2
+
CD133
+
 melanoma cells in the BM of tumor 
bearing mice (Fig. 22) as well in this organ from mice without visible skin tumors 
(Fig. 21).  
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Figure 21. Memory CD4
+
 T cells co-localized with TRP-2+  cells in the BM of mice 
without macroscopic tumors. Smear technique and multicolor IF staining was performed to 
analyze TRP-2 (blue), CD45RB (green), CD133 (red) and CD8
+
 (pink). On the right picture is 
represented the merged of all four dyes. CD45RB¯CD8+  T cells were associated with TRP-2+  
single melanoma cells. The white square shows the place of interaction between CD4
+
 T cells 
and TRP-2
+ 
cells.  
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Figure 22. Memory CD4
+
 T cells co-localized with TRP-2+  cells in the BM of mice with 
macroscopic tumors. Smear technique and multicolor IF staining was performed to analyze 
TRP-2 (blue), CD45RB (green), CD133 (red) and CD4 (pink). The white squares show the 
place of interaction between CD4
+
 T cells and TRP-2
+ 
cells.  
 
20. Perforin and IFN--producing CD8+ T cells in the BM 
 
To investigate whether CD8
+
 T cells associated with melanoma cells can possess 
effector function producing IFN- or perforin, we analyzed smears from the BM of ret 
transgenic mice. We found IFN--producing CD8+ T cells co-localized with TRP-2 
melanoma cells (Fig. 23) but not with TRP-2
+
CD133
+
 cells. Interestingly, analyzing 
the BM of mice without visible skin tumors, we found that CD8
+
 T cells located 
within the large cluster of 50 TRP-2 melanoma cells were unable to produce both 
perforin and IFN- (Fig. 24). Moreover, evaluating TRP-2 specific CD8+ T cells by 
dextramer staining, we detected these cells in the BM failed to observe their 
co-localization with TRP-2
+
 melanoma cells (Fig. 25). These findings suggest that 
tumor microenvironment might neutralize CD8
+
 T cell reactivity. 
Results 
73 
 
   
 
Figure 23. Evaluation of perforin and IFN--producing CD8+  T cells in the BM of tumor 
bearing mice. Smear technique and multicolor IF staining was performed to analyze TRP-2 
(blue), CD45RB (green), CD133 (red) and CD8 (pink). The white squares show the place of 
interaction between CD8
+
 T cells and TRP-2
+ 
cells.  
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Figure 24. Evaluation of perforin and IFN- production in CD8+  T cells in mice without 
macroscopic primary tumors. Smear technique and multicolor IF staining was performed to 
analyze TRP-2 (blue), perforin (green), IFN- (red) and CD8 (pink). CD8+  T cells located 
within a cluster of melanoma cells were unable to produce both perforin and IFN-. 
 
 
 
 
Figure 25. TRP-2-specific CD8
+
 T cells in the BM of mice without macroscopic tumor. 
Smear technique and multicolor IF staining was performed to analyze TRP-2 (blue), Perforin 
(green), H-2k
b
-TRP-2180-188 dextramer (red) and CD8 (pink). Perforin and IFN--producing 
CD8
+
 T cells localized as single T cells. 
 
Next we analyzed the proportion of CD8
+
 T cells interacting with TRP-2
+
Ki67¯ 
melanoma cells and found that about 15% of memory CD8
+
 T cells interacted with 
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TRP-2
+
Ki67¯ melanoma cells in the BM of mice without and with primary tumors 
(Fig. 26, Table 4). Quantitative analyses revealed that although certain memory CD8
+
 
T cells interacted either with single TRP-2
+
 melanoma cells or the smallest cluster of 
melanoma cells (2-5 TRP-2
+
 melanoma cells), none display staining for perforin. 
Only two TRP-2-specif CD8
+
 T cells were able to produce perforin, but none of them 
were co-localized either with TRP-2
+
 melanoma cells or TRP-2
+
CD133
+
 cells in the 
BM of ret transgenic mice (Fig. 25). 
 
 
Figure 26. CD8
+
 T cells in the BM interacting and non-interacting with TRP-2
+
 
melanoma cells. Smear technique and multicolor IF staining was performed to analyze BM 
cells of tumor bearing mice. TRP-2 (blue), CD8
+
 T cells (red) and Ki67 (pink). The white 
arrows show the place of interaction between CD8
+
 T cells and TRP-2
+ 
cells. 
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Table 4. Interaction between TRP-2
+
 melanoma cells with CD8
+
 T cells in the BM of tumor 
bearing mice. The quantification was done from the fig. 25.  
 
 
 
 
Taken together, our data demonstrate the existence of a fraction of dormant 
CD133
+
 melanoma cells in ret transgenic mice. HIF-1 plays a central role in the 
maintenance of CD133
+
 melanoma cells at the beginning of the tumor formation. A 
subpopulation of CD133
+
 tumor cells co-expressed CD271, considered as another 
melanoma stem cell marker. CD133
+
 melanoma cells shown stronger 
immunosuppressive, metastatic, angiogenic, and melanocyte stemness profile in 
comparison with CD133

 melanoma cells, suggesting a greater biological advantage 
to evade antitumor immunity, to grow and metastasize. Disseminated TRP-2
+
CD133
+
 
melanoma cells in the BM were in a dormant state by the absence of Ki67 and PCNA 
expression and shown an aberrant expression of p16 and p27. None of the 
characterized CD8
+
 T cells (TRP-2-specific CD8
+
 T cells, perforin and 
IFN--producing CD8+ T cells) were co-localized with disseminated BM 
TRP-2
+
CD133
+
 melanoma cells in mice with and without primary skin tumors. 
TRP-2
+
CD133
+
 melanoma cells may not be responsible to maintain memory CD8
+
 T 
cells in the BM. 
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V. Discussion 
 
Malignant melanoma is a very aggressive metastatic tumor originating from 
melanocytes. The metastatic melanoma displays a marked resistance to conventional 
therapies resulting in disappointing clinical outcomes when currently available radio- 
and chemotherapeutic treatment strategies are applied. Furthermore, immunotherapies 
based on antibodies, adoptive T cell transfers, and vaccinations shown promising but 
still poor clinical outcomes to eradicate tumors. These results from early clinical trials 
persuaded investigators to elucidate mechanisms responsible for the failure of tumor 
eradication. The resistance to chemo- radio- and immunotherapy has been attributed 
to the presence of either CSCs or dormant tumor cells. In the present study, we 
investigated CSCs in ret transgenic mouse model of spontaneous melanoma using 
CD133 (Prominin-1), which has been used as a marker of CSCs in various solid 
tumors (130-133). 
The analysis of CSCs markers has been an extensive debate in the current 
protocols for preparing single tumor cell suspensions from primary tumor specimens 
for flow cytometry measurements due to CSC markers are expressed on very few 
tumor cells (103, 125, 270). It was stressed that aggressive protocols may remove 
antigens on the cell surface giving erroneously the impression that only very few 
tumor cells can express CSCs markers (91, 163, 275). Thus, the inclusion of 
aggressive enzymes in the dissociation procedure will result in contamination of the 
negative fraction with cells that actually express the antigen (91). Most of the 
enzymatic protocols use trypsin, which is tremendously aggressive because cleave 
several proteins on the cell surface (124, 163); although other protocols use 
collagenase which are much less aggressive, tumor specimens are also incubated 
longer (0.75-2 h) or followed by short incubation with trypsin (124). Instead of these 
aggressive methods, we used a reliable method to avoid the excision of antigens 
considered as CSC markers. Tumor cells were treated with collagenase II and 
collagenase IV for 15 minutes at 37°C to ensure the preservation of CSC markers on 
the cell surface that resulted in a high yield of live cells (more than 95%).  
Using this optimized protocol we found that primary tumors contain 
approximately 1.5% of CD133
+
 melanoma cells. Indeed, we found that the dormant 
state of CD133
+
 melanoma cells in primary tumors and mLN was dependent on the 
weight of primary skin tumors. CSCs may be responsible to initiate and propagate 
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tumors, so called tumor-initiating cells. CSCs exhibit a higher resistant to chemo- and 
radiotherapy regimens due that they remain mostly arrested in G0/G1 of the cell cycle. 
CSCs and dormant tumor cells have been distinctly defined; however both share the 
particular feature that are mostly arrested in G0/G1 of the cell cycle (189). Therefore, 
we proposed that dormant tumor cells share characteristics and properties of CSCs.  
Interestingly, immunofluorescence staining has shown that CD133+  melanoma 
cells formed smaller clusters predominantly located in peripheral tumor areas where 
these cells could reside for their maintenance (273, 274). Blood vessels are essential 
to supply the nutrients and oxygen, so tumor growth is angiogenesis-dependent (271, 
272). We found an aberrant architecture of blood vessels in peripheral areas of 
primary tumors. This finding is in agreement with other publication showing that 
vascularity of tumor varies tending to be greatest in regions of active growth, 
regularly at the periphery (276). The abnormal nature of tumors results in abnormal 
blood vessels. Tumor vessels are variable in size, shape and branching pattern and are 
not organized in conventional hierarchy of arterioles, capillaries and venules (277). 
Compared with quiescent established blood vessels, endothelial cells in angiogenic 
blood vessels can strongly proliferate (278, 279). Furthermore, although blood vessels 
within the tumors are built by existing blood vessels or by incorporation of bone 
marrow progenitor cells (277, 280), it is possible that CD133
+ 
melanoma cells in ret 
transgenic mice may differentiate into endothelial cells (vasculogenesis) to support 
the angiogenesis giving rise to aberrant blood vessels (281-283). This could be 
supported by our finding that CD133
+
 melanoma cells express VEGFR2, a receptor 
that recognizes VEGF (282, 283). Moreover, we observed that large primary tumor 
collected in ret transgenic tumor bearing mice were consistently bloody. Rapid 
endothelial cell proliferation contributes to the instability of tumor vessel walls 
leading to hemorrhage described as tumors particularly bloody (277). In addition, it 
has been recently shown that sequencing of tumor genomes from different areas of the 
same tumor reveal striking intratumoral genetic diversification which may lead to 
functional specialization among cancer cells (284, 285). The presence of CD133+  
melanoma cells in peripheral tumor areas, where aberrant blood vessels were 
localized, may indicate that these zones might be the niche for CD133+  melanoma 
cells (279, 281, 286), at least in ret transgenic melanoma model. Nevertheless, further 
experiments are needed to confirm these observations.  
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Interestingly, we found a higher rate of proliferation of CD133
+
 melanoma cells 
in mLN compared to those in primary tumors from mice with advanced tumors. These 
findings suggest that melanoma cells in mLN probably may also colonize their tumor 
of origin in the process called “tumor self-seeding” (287). Self-seeding of melanoma 
cells is mediated by aggressive circulating tumor cells and can accelerate primary 
tumor growth and angiogenesis, and could explain relationship between anaplasia, 
tumor size, vascularity, and local recurrence (12). It would be interesting to 
investigate whether CD133
+
 melanoma cells possess these self-seeding properties. We 
do not discard other mechanisms that may promote the growth of primary tumors. 
We also found that HIF-1 might play an important role in the maintenance of 
CD133
+
 melanoma cells, mainly in early stages of tumor formation where tumor cells 
are poorly vascularized and in advanced tumors where hypoxia (1% oxygen) occurred 
due to the inevitable outcome of the rapidly growing tumors (156). Restricted oxygen 
conditions increase the CSC fraction and promote acquisition of a stem-like state 
(288). Here we detected CD133
+
HIF-1+ melanoma cells which could be maintained 
by hypoxic conditions. In addition, we found that CD133
+
 melanoma cells displayed 
higher expression of CXCR4 than CD133¯ melanoma cells. CXCR4 is considered to 
be a master regulator of metastases (144). Furthermore, our findings are in agreement 
with data of Soeda et al. who showed that the propagation of the glioma-derived 
CSCs in a hypoxic environment led to the expansion of cells bearing CXCR4 (156). 
We suggest that HIF-1 might contribute the maintenance of CD133+ melanoma cells 
in ret transgenic mice by activating adaptive transcriptional programs that promote 
cell survival, motility, tumor angiogenesis and self-renewal capacity. Indeed, we 
demonstrated that CD133
+
HIF-1+ melanoma cells had a higher rate of proliferation 
at earliest stages of tumor progression both in primary tumors and mLN. Moreover, it 
has been shown that hypoxia induces an embryonic stem cell (ESC)-like 
transcriptional program including Oct4, Nanog, Sox2, Klf4, c-Myc in cancer cell lines 
from brain, kidney, cervix, lung, colon, liver and breast tumors (289). In hypoxic 
glioma cell line U251, Mathiel et al. observed an upregulation of CD133, a glioma 
stem cell marker accompanied by a consistent increase of Nanog and c-Myc 
expression (289). It is known that glioma (originated from glial cells) and melanoma 
(originated from melanocytes) share many cell surface markers due to both have 
arisen from melanoblasts, those precursor derived from the embryonic neural crest (71, 
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77, 78).  
It is important to note that CD271 has been recently described as an important 
CSC marker, especially in melanoma with an increased tumor-initiating capacity as 
compared with CD271¯ tumor cells (124). We found that primary tumor had an 
elevated number of TRP-2
+
CD133
+
CD271
+
 melanoma stem-like cell fraction in 
proliferative state compared to mLN. However, mLN showed elevated numbers of 
TRP-2
+
CD133
+
CD271
+
 melanoma cells in proliferative state in early stages of tumor 
progression in comparison to primary tumors. The proliferative capacity of 
TRP-2
+
CD133
+
CD271
+ 
cells is restricted in advanced tumors, where the tumor bulk is 
already well-established. In this respect, it has been reported that CD271
+
 melanoma 
cells can be multipotent and capable to establish the heterogeneity of parental tumor, 
retaining the self-renewal property.  Furthermore, CD271
+
 melanoma cells could be 
passaged more than 5 retransplantations and CD271
+
SOX10
+
 melanoma cells 
correlated with higher metastatic potential (125). We believe that CD133
+
CD271
+
 
melanoma cells might possess CSCs properties in ret transgenic tumor-bearing mice. 
Analyzing other potential cancer stem cell markers, we found that high amounts of 
tumor cells expressed CD20, nestin and ABCB5, whereas CD34 and CD166 were 
presented only on a small tumor cell subset. It has been shown that 
ABCB5-expressing melanoma cells exhibit multidrug resistance (MDR) features (119, 
123). The most common cause of MDR in human cancers is the functional expression 
of one or more ATP-binding cassette (ABC) transporters that efflux (extrusion of toxic 
substances outside the cell) anticancer drugs from the tumor cells (122, 216). Thus, 
ABCB5
+
 melanoma cells in ret transgenic mice may display MDR features.  
Since primary tumors and mLN contain CD133
+
-expressing melanoma cells, we 
addressed the question of the biologic function of these cells. It was found that 
immunosuppression-related markers (PD-L1, CTLA-4, CD39 and CCR4), 
angiogenic-related marker (VEGFR2), metastatic-related markers (CXCR3 and 
CXCR4) and melanocyte stemness-related maker (CD34) were strongly expressed on 
CD133
+
 cells as compared to CD133¯ counterparts. These findings demonstrate that 
interactions between tumor cells and host immune cells in the tumor 
microenvironment create an immunosuppressive state in which CD133
+
 melanoma 
cells might actively participate inducing the immunosuppression and promoting an 
evasion from immunosurveillance due to their malignant potential (234-236). Thus, 
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dormant CD133
+
 melanoma cells may then enter the escape phase, which correspond 
to clinically apparent disease. In the escape phase, CD133
+
 melanoma cells might 
contribute to the formation of tumor bulk.  
Once dormant / slow-cycling CD133
+
 cells evaded antitumor immunity, they 
might acquire the capacity to produce tumor cell clones to proliferate rapidly. For an 
efficient proliferation, these tumor cells require of blood vessels. Dormant termination 
of tumor cells has been reported by the overexpression of VEGF (291). Thus, the 
expression of VEGFR2 on CD133
+
 melanoma cells could promote angiogenesis. 
Furthermore, CD133
+
 melanoma cells may metastasize to distant organs through the 
expression of CXCR3 and CXCR4. We observed that CD133
+
 melanoma cells in 
primary tumors and mLN possessed a higher expression of VEGFR2, CXCR3 and 
CXR4 than CD133¯ melanoma cells. These findings explain, at least in part, why the 
metastatic potential of primary melanoma is considerably higher than that of other 
solid tumors (146). Around 60% of metastasis was reported to be located in regional 
lymph nodes in malignant melanoma (142). It was demonstrated that CXCR3 plays a 
critical role in lymph node metastasis of melanoma (B16F10 cell line) (142), and that 
CXCR4
+
CD133
+
 B16/F10 melanoma cells exhibited higher metastatic capacity than 
CXCR4
¯
CD133
+ 
counterparts (157). Moreover, patients with tumor double positive 
for CXCR3 and CXCR4 were reported to have significantly poorer prognosis than 
those with tumors positive only for CXCR4 or the double negative (144). 
Furthermore, CD133
+
 melanoma cells have a pronounced expression of the 
murine melanocytic stem cell marker CD34, providing an additional biological 
advantage to retain the melanocyte stemness phenotype and probably the machinery 
necessary to maintenance the stem-like cell character. In this regard, it would be 
interesting to investigate the expression of the typical stem cell makers such as Oct-4 
Sox-2, Kfl-4, Nanog on CD133
+
 melanoma cells in ret transgenic mice. 
In ret transgenic mouse melanoma model, a majority of mice older than 20 weeks 
without macroscopic tumors contained TRP-2-positive disseminated melanoma cells 
both in the BM and lymph nodes and showed no further melanoma progression. These 
reports argue for a potential role of dormant tumor cells in the maintenance of a 
long-term persistence of tumor antigen-specific memory T cells, which could restrict 
tumor growth in vivo (228, 232). In this study, TRP-2+CD133+-expressing cells were 
analyzed in the BM of tumor bearing mice. We found that TRP-2+CD133+  melanoma 
A A 
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stem-like cells represented only 0.238% and 0.31% from all disseminated melanoma 
cells in mice without and with macroscopic tumors, respectively.  
To study the dormancy state of TRP-2+CD133+  melanoma stem-like cells in the 
BM of ret transgenic mice, we analyzed several proteins evolved in the progression of 
the cell cycle including p16 and p27 expression which have been described as 
cyclin-dependent kinase inhibitors (CDKI) (292). We also analyzed the proliferating 
cell nuclear antigen (PCNA) and the Ki67 antigen. We observed cytoplasmic staining 
of p16. It is well-established that p16 protein acts as cell cycle inhibitor in the nucleus. 
However in breast cancer, cytoplasmic accumulation of p16 identifies a subset of 
tumor cells with accelerated proliferation (293). In addition, nuclear and cytoplasmic 
p16 overexpression in breast cancer was associated with a highly malignant 
phenotype (293). Moreover, we found membranous and cytoplasmic staining of Ki67 
in same BM single tumor cells. Cell membrane and cytoplasmic staining of Ki67 has 
been described in invasive breast carcinoma and adenoma of the thyroid gland 
associated with tumors that are high grade (294). Cytoplasmic localization of p27 was 
identified as well, providing additional evidences that CD133
+
 melanoma cells may 
be highly tumorigenic (295). These data demonstrated that TRP-2+CD133+  melanoma 
stem-like cells are in a dormant state and possess an aberrant expression of Ki67, p16 
and p27 in the BM.  
It has been reported that the BM could be a major site for long-term persistence 
of tumor-specific memory T cells that could interact with disseminated tumor cells 
(228). Here we have demonstrated direct cell-cell contact between BM TRP-2
+
 tumor 
cells and memory CD8
+
 T cells. It has been proposed that disseminated BM TRP-2
+
 
tumor cells which probably might be in a dormant state, could be responsible in the 
maintenance of TRP-2-specific memory CD8
+ 
T cells and functionally active 
TRP-2-specific, effector memory CD8
+
 T cells in ret transgenic mice without visible 
primary tumors but with disseminated tumor cells. Therefore, these cells might 
stimulate the formation of melanoma-reactive CD8
+
 T cells which restrict the growth 
of macroscopic primary tumors (232) and block the progression of metastases, 
keeping the animals in the equilibrium phase, in agreement with the 
immunosurveillance theory (207). 
Memory CD8+T cells (CD8+CD44
high
) were co-localized with TRP2+  melanoma 
cells, where the proportion of memory CD8+  T cells interacting with TRP-2+  
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melanoma cells was lower (less than 15%). These findings suggest that memory 
phenotype of CD8+  T cells might be induced by TRP-2+  melanoma cells. However 
we did not find memory CD8+  T cells co-localized with disseminated TRP-2+CD133+  
melanoma stem-like cells in the BM of mice with and without macroscopic primary 
skin tumors. In addition, we found that memory CD4+  T cells (CD4+CD45RB
¯
) had 
direct contact with TRP-2+  melanoma cells but not with TRP-2+CD133+  melanoma 
stem-like cells in the BM of mice with and without macroscopic primary skin tumors. 
Moreover, we found that none of the TRP-2-specific, perforin-producing CD8+  T 
cells were co-localized either with TRP-2+  melanoma cells or TRP-2+CD133+ 
melanoma stem-like cells in the BM of mice with and without macroscopic primary 
skin tumors. Furthermore, we could only find IFN--producing CD8+  T cells 
co-localized with TRP-2+  melanoma cells but not with TRP-2+CD133+melanoma 
stem-like cells. Interestingly, analyzing the BM of mice without macroscopic primary 
skin tumors, we found CD8+  T cells co-localized within one large cluster of TRP-2+  
melanoma cells (50 TRP-2+  tumor cells). Nevertheless these CD8+  T cells were 
unable to produce intracellularly both perforin and IFN-. These findings suggest that 
tumor microenvironment might neutralize CD8+  T cell reactivity. 
Therefore, these data indicated that none of the characterized CD8+  T cells 
(TRP-2-specific CD8
+
 T cells, perforin and IFN--producing CD8+ T cells) were 
co-localized with disseminated BM TRP-2+CD133+  melanoma stem-like cells in mice 
without and with primary skin tumors. We suppose that memory CD8+  T cells in the 
BM might be maintained by both single melanoma cells and the smallest cluster of 
melanoma cells. Large melanoma cell cluster may induce inactivation of CD8
+
 T cells, 
as was shown by the lack of intracellular production of IFN-. The indeterminate 
dormant phenotype of TRP-2+CD133+  melanoma stem-like cells may be a crucial 
mechanism to the maintenance of memory CD8
+ 
T cells for a long period of time. 
It has been shown that BM displays structural and functional features of a 
secondary lymphoid organ, contains follicle-like structures similar to lymph nodes or 
spleen and can initiate not only primary, but also secondary T-cell responses (296). 
Thus, cell-cell contacts between TRP-2
+
 melanoma cells and memory CD8
+
 T cells 
may stimulate secondary immune responses (which is faster and stronger than 
primary immune responses) and subsequently protective anti-tumor immunity by 
promoting melanoma-specific effector memory CD8
+
 T cells. The effector reactivity 
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of these CD8
+
 T cells may occur systemically and/or in the tumor microenvironment 
(296) and not within the BM, where they fail to produce perforin. 
Taken together, we provide evidence that CD133
+
 melanoma stem-like cells 
might modulate immune responses in primary tumors and lymph node metastasis. The 
data also suggests that HIF-1 plays a central role in the maintenance of CD133+ 
melanoma cells. Disseminated TRP-2
+
CD133
+
 melanoma in the BM are in the 
dormant state having an aberrant expression of p16 and p27 due to their cytoplasmic 
localization. Finally, none of the characterized CD8
+
 T cells (TRP-2-specific CD8
+
 T 
cells, perforin and IFN--producing CD8+ T cells) were co-localized with 
disseminated BM TRP-2
+
CD133
+
 melanoma stem-like cells in ret transgenic mice. 
These results suggest that TRP-2
+
CD133
+
 melanoma cells may not be responsible to 
maintain memory CD8
+
 T cells in the BM. 
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VII. Abbreviations: 
 
A 
APC   Antigen-presenting cell 
ALDH   Aldehyde dehydrogenase. Putatite cancer stem cell marker. 
ABCB5 ATP-binding cassette sub-family B member 5 also known as 
P-glycoprotein. Putative melanoma stem cell marker 
Ab    antibody 
 
B 
BM    bone marrow 
BSA   bovine serum albumin 
B-RAF   B-Raf proto-oncogene serine/threonine-protein kinase 
B16F10   melanoma cell line from a mouse model of melanoma metastasis 
bFGF   basic fibroblast growth factor 
 
C  
CSCs   cancer stem cells 
CCL   chemokine ligand 
CTLA-4  cytotoxic T lymphocyte antigen- 4 
CCR   chemokine receptor 
CD    cluster of differentiation 
cm    centimeter 
CFS   carboxyfluorescein (similar to FITC) 
CTL   cytotoxic T lymphocyte 
°C    degree Celsius 
CD4 It serves as a co-receptor for the TCR (on T cells). Together with 
the TCR, CD4 binds to a class II MHC protein (on APCs). 
CD8 It serves as a co-receptor for the TCR (on T cells. Together with the 
TCR, CD8 binds to a class I MHC protein (on APCs). 
CD45RB It plays a critical role in TCR and BCR signaling. As T cells 
become activated and progress from naïve to memory cells, 
CD45RB expression is downregulated. 
CD62L L-selectin. It is a cell adhesion molecule found on lymphocytes. 
CXCR3 C-X-C chemokine receptor type 3. CXCR3 is able to regulate 
leukocyte trafficking. 
CXCR4 C-X-C chemokine receptor type 4. alpha-chemokine receptor 
specific for stromal-derived-factor-1 (SDF-1 also called CXCL12) 
CD20 Expressed on the surface of all B-cells beginning at the pro-B phase. 
It is considered as putative CSC marker  
CD24  Expressed at the surface of most B lymphocytes and differentiating 
neuroblasts. It is considered as putative CSC marker. 
CD31 Endothelial cell marker. It is used as indicator of vasculatization. 
CD34   Melanocyte stem cell marker (in mouse) 
CD39   ectonucleoside triphosphate 
CD44 It is a cell-surface glycoprotein involved in cell-cell interactions, 
cell adhesion and migration. CD44 expression is an indicative 
marker for effector-memory T-cells. 
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CD73 ecto-5´-nucleotidase is a glycosyl-phosphatidylinositol-linked cell 
surface enzyme  
CD80   B7.1 expressed on antigen-presenting cells (APCs) 
CD86    B7.2 expressed on antigen-presenting cells (APCs) 
CD133   Prominin-1, putative CSCs marker 
CD152   CTLA-4 (cytotoxic T lymphocyte antigen- 4) 
CD166 Activated leukocyte cell adhesion molecule. It is considered as 
putative CSC marker 
CD271 Nerve growth factor receptor (NGFR). It is considered as putative 
melanoma stem cell marker. 
CD274   PD-L1 (programmed cell death-1). 
CDK4   cyclin dependent kinase 4 
CDKN2A  cyclin-dependent kinase inhibitor 2A 
CDK4/6   cyclin-dependent kinase 4/6 (important for cell cycle regulation) 
CDKI   cyclin-dependent kinase inhibitors 
 
 
D 
DAPI   4,6-diamidino-2-phenylindole (blue dye) 
DC    dendritic cell 
DMSO   Dimethylsulfoxid 
DNA   deoxyribonucleic acid 
DNAase -I  Deoxyribonuclease-I 
 
H 
HSC   Hematopoietic stem cell (s) 
H-2k
b
TRP-2180-188 MHC dextramers H-2K
b
TRP-2180-188 which recognize 
TRP-2-specific CD8
+
 T cells 
 
E 
EDTA   Ethylenediaminetetraacetic acid 
E2F   Elongation Factor 2 (a family of transcription factors) 
 
F 
FACS   fluorescent activated cell sorting 
FCS   fetal calf serum 
FITC   fluorescein-5-isothiocyanate 
FMO    fluorescence minus one 
FSC   forward scatter 
Fc Fragment crystallizable region. It is the tail region of an antibody 
that interacts with cell surface receptors called Fc receptors and 
some proteins of the complement system. 
 
G 
g    gram 
g    acceleration due to gravity, 
    g = 9,81m/s2 
GM-CSF  granulocyte/macrophage  colony stimulating factor 
gp100   glycoprotein 100, a melanoma-associated antigen 
G1/S   Gap / Synthesis (cell cycle phase) 
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H 
h    hour 
HIF-1   hypoxia-inducible factor 1 
HSCs   hematopoietic stem cells 
Hoechst   solution for the cell nuclear staining 
H-2K
b
 murine MHC antigen. H-2K
b
 is involved in antigen presentation to T 
cells expressing CD3/TCR and CD8 molecules. 
 
I 
IF    immunofluorescence 
IF-buffer  immunofluorescence buffer 
IF-gs   IF-buffer plus 2% of goat serum in IF-buffer 
IFN    interferon 
IFN-    Interferon alpha 
IFN-    interferon gamma 
Ig    Immunoglobulin 
IgG    Immunoglobulin isotype G 
IgG,   Immunoglobulin isotype G with a kappa light chain 
IL    Interleukin 
IL-6   Interleukin-6 
IL-10   Interleukin-10 
IL-11   Interleukin-1 
Ipilimumab  Therapeutic antibody against CTLA-4 
iPS    induced pluripotent stem cell 
 
K 
Ki67   proliferation marker 
 
L 
l    litter 
 
M 
MAA   melanoma-associated antigen 
MAPK   mitogen activated protein kinase 
mAb   monoclonal antibody 
MDSCs   myeloid-derived suppressor cells 
MEK   MAP-ERK kinase 
MART-1 Melanoma-associated antigen recognized by T cells (also known as 
Melan-A). 
MHC   major histocompatibility complex 
MITF   microphthalmia-associated transcription factor 
mLN   metastatic lymph nodes 
MDR   Multidrug resistance 
MT    mouse metallothionein-I (MT) promoter-enhancer 
M    molar (mol/l) 
ml    milliliter 
mg    milligramm 
mm    millimeter 
Abbreviations 
100 
µm    micrometer 
µg    microgramm 
μl     microliter 
ml     milliliter 
μg    microgram 
mg    milligram 
min    minute 
 
N 
nevi    Moles (Moles, also known as melanocytic nevus, plural: nevi) 
NK    natural killer cells 
NO    nitric oxide 
nm    nanometer 
 
O 
Ova   ovalbumin 
 
P 
Pen/Strep  penicillin/streptomycin 
%    percent 
pg    picogram 
PBS   phosphate buffered saline  
PE    phycoerythrin 
PD-1   programmed cell death-1 
PD-L1   Programmed cell death 1 ligand 1 (CD274 or B7-H1) 
PCNA   proliferating cell nuclear antigen 
PTEN    Phosphatase und Tensin homolog 
PTHRP   parathyroid hormone related protein 
 
R 
RANKL  receptor activator of nuclear-factor-kB ligand 
ret    human ret proto-oncogene 
rpm    revolutions per minutes 
RNA   ribonucleic acid 
RT    room temperature 
 
S 
SSC   side scatter 
 
T 
TCR   T-cell receptor 
TILs   tumor-infiltrating lymphocytes 
TGF   transforming growth factor 
TNF   tumor necrosis factor 
Treg   regulatory T cell 
TRP   tyrosinase related protein 
TRP-2180-188  TRP-2 sequence / TRP-2 peptide 
TRP-1    Tyrosinase-related protein 1 gp75)  
TRP-2   tyrosinase-related protein 2 (dopachrome tautomerase)  
TLR   Toll-like receptor 
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Tu    tumor (specimenes collected from primary tumors) 
Tyr    tyrosinase 
 
V 
VEGF   vascular endothelial growth factor 
VEGFR1, 2  vascular endothelial growth factor receptor type 1 or 2 
VCAM-1  vascular cell adhesion molecule-1 
VLA-4   very late activation antigen-4 
V600E  Mutations resulting in a substitution of valine for glutamate at 
amino acid 600 
V    volume 
v/v    volume per volume 
 
U 
UV    ultraviolet 
 
W 
WT    wild type 
Wnt Portmanteau of Int and Wg wingless in Drosophila melanogaster, 
which is the best characterized Wnt gene 
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